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Abstract
Smith, James Keaton. Ph.D. The University of Memphis. May 2014. An
Evaluation of Chitosan Paste as an Injectable and Adhesive, Adjunctive Therapy for
Musculoskeletal Wound Infection Prevention. Major Professor: Warren O. Haggard,
Ph.D.
Musculoskeletal wound infection as a result of traumatic injury is a life
threatening condition that occurs in both military and civilian environments. Standard
treatment is lifesaving first aid to stabilize a patient’s vital signs, followed by surgical
intervention including debridement, irrigation, and systemic antibiotic therapy. After
surgical intervention, if no infection is evident, hard tissues are stabilized and the wound
is closed. Adjunctive therapy via local drug delivery of antibiotics is beneficial in
musculoskeletal wounds to prevent infection establishment where the penetration of
antibiotics is prohibited by compromised vasculature. Local antibiotic delivery, using the
biomaterial chitosan, has the potential to provide a biodegradable and non-cytotoxic
solution compared to other, current drug delivery devices. A newly developed, mildly
acidic, chitosan paste will function as a biodegradable, non-toxic, as well as injectable
and adhesive, antibiotic delivery device for infection prevention in musculoskeletal
wounds. The objective of the work presented herein, was to evaluate the chitosan paste
device’s characteristics and functional abilities in vitro and in vivo. The in vitro analysis
demonstrated the chitosan paste’s ability to be applied by injection from taper-tip syringe
and be adhesive in clinically relevant situations. The paste was able to incorporate and
release antibiotics, while degrading without a prolonged cytotoxic effect. In vivo analysis
in a rat, intramuscular, biocompatibility model indicated that additional chitosan paste
formulation, specifically the acidic to neutralized product ratio, is needed to improve
biocompatibility, while an infection prevention, mouse biofilm model demonstrated the
v

device was effective at reducing bacterial load. These results led to the conclusion that,
with further study and optimization, the chitosan paste shows potential as an adjunctive,
local, infection prevention therapy to standard surgical debridement, irrigation and lavage
treatment for bacterial contaminated musculoskeletal wounds.
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Preface
This dissertation is composed of several manuscripts which have been or will be
submitted for publication. The Introduction (Chapter 1), Research Narrative (Chapter 2),
Conclusions (Chapter 6), and Recommendations for Future Work (Chapter 7) are texts
unique to this dissertation, serving to unify the included manuscripts, with references for
these sections located in the Bibliography (Chapter 8). The manuscript in Chapter 3
entitled “Effects of Sodium Acetate Buffer on Chitosan Sponge Properties and In Vivo
Degradation in a Rat Intramuscular Model” was submitted to Journal for Biomedical
Materials Research Part B (February 2014). The work included in Chapter 3 was funded
by the Department of Defense, Defense Medical Research and Development Program
grant number W81XWH-12-2-0020, titled “Antibiotic-loaded biopolymer sponge for
prevention of polymicrobial wound infection.” The manuscript in Chapter 4 entitled
“Fabrication and In Vitro Evaluation of Chitosan Paste as a Potential Injectable and
Adhesive Local Antibiotic Delivery Device” will be submitted to Journal for Biomedical
Materials Research Part B. The manuscript in Chapter 5 entitled “In Vivo
Biocompatibility and Infection Prevention of an Injectable and Adhesive Chitosan Paste
Device” will be submitted to Journal of Orthopaedic Research. The manuscript in
Appendix 1 entitled “Chitosan Sponges for Local Synergistic Infection Therapy: A Pilot
Study” has been published in Clinical Orthopaedics and Related Research (Oct
2013;471:3158-62). The manuscript in Appendix 2 entitled “Chitosan Coating to
Enhance the Therapeutic Efficacy of Calcium Sulfate-Based Antibiotic Therapy in the
Treatment of Chronic Osteomyelitis” has been submitted to Journal of Biomaterial
Applications (April 2014).
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Chapter 1
Introduction

Background
A musculoskeletal wound is an injury that prevents the natural function of the
body’s bone and muscle tissue, caused by traumatic laceration, puncture, crush, burn or
even surgical incision.1,2 Whether in a military or civilian setting, musculoskeletal
wounds are often associated with compromised vasculature and exposure to bacterial
contamination from the environment.3,4 Contaminating bacteria proliferate among the
avascular, non-viable, wound tissues resulting in an established musculoskeletal wound
infection, which may be further complicated by antibiotic resistant bacterial strains or
biofilm formation.3,5 The infection of a musculoskeletal wound impairs wound healing,
may lead to sepsis, and if not treated, could result in loss of limb or life, placing an
additional economic burden on the patient and society. 2,3,6-8
One in ten American civilians will visit an emergency department each year for
treatment of musculoskeletal wounds, which is a leading cause of death in Americans up
to 34 years old and is among the leading causes of death in all age groups. 2 In the United
States of America’s recent military engagements, soldiers have sustained more than 25
thousand nonlethal wounds, primarily due to high-energy gunshot or explosive trauma.9,10
Hundreds of billions of dollars are spent annually treating these civilian and military
wounds, with costs continually on the rise.3,11,12 Although the pathology and treatment of
musculoskeletal wounds and their infections is similar, the incidence differs between
civilian and military environments. In the battlefield, infection occurs in roughly 26.5%
of musculoskeletal wounds,3,11 as high as 65% when open fractures are present,5,13 and
1

has an even higher likelihood when biomaterials are applied for wound stabilization or
closure.14 Treatment costs of infected musculoskeletal wounds are an added economic
burden on the patient and society.15-17 Addressing this clinical problem using low cost
and effective infection prevention methods should reduce the socioeconomic burden by
improving the patient’s quality of life.
Preliminary treatment for severe, open, musculoskeletal wounds is lifesaving first
aid.3,18 Sterile dressings are used to cover open wounds until surgical intervention, while
systemic antibiotic therapy is initiated as soon as possible.19 Surgical intervention
includes debridement, or the removal of foreign contaminates and non-viable tissue, and
irrigation which both reduce the wound’s bacterial load.7,20,21 After surgical intervention,
wound closure may be delayed until it is evident that all infection is cleared.20,22
Compromised vasculature and decreased blood circulation in severe musculoskeletal
injuries reduces systemic antibiotic efficacy due to the distance and biochemical
environments that the drug must traverse to reach the infection site. Achieving
bactericidal concentrations in these wound sites require increased systemic antibiotic
dosing, which increases the likelihood for their toxic side effects.5,23-25 Emergency care,
early surgical intervention, systemic antibiotics, fracture fixation, and eventual wound
closure are standard treatments for preparing musculoskeletal wounds to heal.19,22
Optimal local antibiotic therapy provides high levels of active antibiotics to the
infected location with low, systemic antibiotic levels.26,27 Systemic antibiotic delivery
techniques have reduced infection prevention efficacy in vascular compromised,
musculoskeletal wounds in comparison to local antibiotic diffusion using a drug delivery
device. Optimal adjunctive, local antibiotic therapy provides elevated antibiotic
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concentrations to the local wound environment without reaching toxic systemic
concentrations26-29, keeping the wound site infection free during the time between injury
and primary closure, approximately three to seven days.23,27 Standard local drug delivery
treatments often require removal of the non-degraded carrier, result in toxic degradation
byproducts, or are limited in antibiotic loading choices.30 Polymethylmethacrylate bone
cement is a standard biomaterial for local antibiotic delivery in structurally compromised
musculoskeletal wounds.23,31 In a bead form, polymethylmethacrylate provides
predictable but characteristically poor antibiotic release with high initial concentrations
followed by a rapid decline to sub-inhibitory concentrations.32 Additionally, this nondegradable material must be removed before wound healing may begin. 23,33 Another
standard, local, antibiotic delivery material is calcium sulfate. 34,35 Although calcium
sulfate dissolves to create an osteoconductive environment, it increases wound
drainage.36,37 Antibiotics incorporated into calcium sulfate are very quickly and nearly
completely released as the material dissolves, with the antibiotic concentration rapidly
declining to sub-inhibitory levels.35,38 Biodegradable, local drug delivery alternatives,
such as chitosan devices, potentially have increased efficacy as they may deliver a
complete dose of multiple antibiotics and make device removal unnecessary.23,39
Chitosan is a naturally occurring, linear polysaccharide composed of randomly
distributed β-(1-4)-2-amino-2-D-glucosamine (deacetylated) and β-(1-4)-2-acetamido-2D-glucoseamine (acetylated) units (see appendix 3, Figure 1 for the molecular
structure).40,41 The major procedure for obtaining chitosan is the alkaline deacetylation of
chitin. One source of chitin is from the exoskeletons of shellfish, especially shrimp,
making it readily available and inexpensive. 41,42 Generally, chitin has less than 50%
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deacetylated units, while chitosan has greater than 50% deacetylated units.40,41 Chitosan
typically becomes increasingly resistant to degradation as the degree of deacetylation
increases.43-45 In the body chitosan is degraded either enzymatically or by acid
dissolution.40,46 Lysozyme’s enzymatic degradation of chitosan occurs by cleaving the
glycosidic bonds between repeating units into biocompatible saccharides and
glucosamines.44,47 Chitosan is a cationic weak base, soluble in dilute, organic acid
solutions with some bioadhesive properties.41,48,49 Chitosan, in many forms, is
characterized as being able to store and release drugs over time.40,41
Chitosan has numerous applications in cosmetics, agriculture, food, and textile
industries.42 Additionally, chitosan is being used or investigated for numerous medical
applications.40,47 The University of Memphis, Department of Biomedical Engineering has
researched multiple chitosan devices with potential medical applications, such as films
and coatings for musculoskeletal implant fixation hardware,50,51 beads having some
mechanical strength as a drug delivery device, 52 mats as guided tissue regeneration
scaffolds,53 and sponges as drug delivery wound dressings.39,54,55 The problem of
musculoskeletal wound infection places an increased burden on an injured patient, and
society as a whole, indicating the need for an economically and clinically-effective
adjunctive therapy for infection prevention, resulting in the development of the chitosan
paste as reported in this body of work. In the literature, there have been few
investigations into chitosan as an injectable, drug delivery material, with most devices
developed as a crosslinked or composite material including chitosan, and tested in in vivo
wound healing animal models.43,56-62 Injectable chitosan devices have highly variable
degradation rates in in vivo models,43,56 with one researched device eliciting an immune
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response.57 Preliminary in vitro analyses of the same devices are even more uncommon in
the literature. For the chitosan paste device investigated in this body of work, prototype
versions were fabricated and investigated for in vitro material characteristics and device
functionality as an injectable, adhesive, biodegradable and biocompatible, local antibiotic
delivery device. The chitosan paste was also analyzed in vivo to confirm the device’s
biocompatibility and infection prevention characteristics.
Hypothesis
The application of the adjunctive, local drug delivery, chitosan paste device to an
open musculoskeletal wound will prevent infection establishment. The chitosan paste
should be injectable, adhesive, biocompatible, able to store and release antibiotics, and
biodegradable.

5

Chapter 2
Research Narrative

Musculoskeletal wounds are a common occurrence, often caused by falls in
civilian environments, explosions on the battlefield, or gunshots which occur frequently
in both settings.1,11 It has been estimated that one in every ten Americans will visit the
hospital every year for a musculoskeletal wound and there have been over 50,000
musculoskeletal wounds to American soldiers in Operation Iraqi Freedom and Operation
Enduring Freedom.9 Musculoskeletal wounds are one of the leading causes of death in all
age groups in the United States.11 Contaminating bacteria and resulting infections further
complicate musculoskeletal wounds which are estimated to have a 20% chance of
infection in the civilian population, whereas complex, open musculoskeletal wounds
stand a 60% chance for infection in the military population.3,5,12 Musculoskeletal .wound
infections are both a physical and socioeconomic burden for patients and society.11
The standard treatment for a patient with a complex musculoskeletal wound is
lifesaving first aid, hemostasis and treatment for shock.18 After transport to a medical
facility, systemic antibiotics are immediately administered intravenously. 19 Surgical
intervention includes at least one round of debridement and irrigation in order to remove
non-viable tissue and reduce bacterial load in the wound site.21 Internal or external
fixation is then used to structurally stabilize the musculoskeletal wound, which is closed
only after attending physicians are confident there is no infection present. 22 Compromised
vasculature may be present to some degree in the musculoskeletal wound, preventing
adequate blood flow and systemic antibiotic’s access to the wound site. 20,27 Increasing
antibiotic dosages to diffuse bactericidal levels to the local wound environment increases
6

the chance for antibiotic toxicity to the patient. Local antibiotic drug delivery achieves
high concentrations of antibiotics to the local environment by diffusion without causing
toxic systemic antibiotic dosages.29
Additional complications toward effectively preventing musculoskeletal wound
infections are the rise of antibiotic resistance and biofilm forming bacterial strains.
Bacteria are developing resistances to antibiotics faster than in the past and are moving
from hospital settings to contaminating patients in the community. 63 Biofilm forming
bacteria have an additional, physical level of protection against antibacterial agents. 14,24
The combination of bacterial biofilm formation and antibiotic resistance, the efficacy of
systemic antibiotics to reach and prevent infection in a musculoskeletal wound further
diminishes, while the need for effective therapies remains high.
There are many implantable materials that have been investigated for local drug
delivery. The most commonly used is a polymer, polymethylmethacrylate (PMMA)
which is not degradable inside the body and has poor drug release characteristics.23,31 The
ceramic calcium sulfate is a degradable drug delivery device, that provides an
osteoconductive environment, however this material also has poor drug release properties
(see Appendix 2).34,35 Other degradable polymers, such as polylactic acid,
polycaprolactone, poly(lactic-co-glycolic) acid, and collagen hydrogels, are used or
modified to form drug delivery devices and produce desired material properties, such as
drug release or degradation rate, but negatively affect the material’s biocompatibility. 64
This body of work focuses on the polymer chitosan to produce local drug delivery
devices.40 Chitosan is a cationic copolymer composed of two subunits distributed
throughout the molecule with the molecular structure effecting its degradability,
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biocompatibility and other functional properties.41 Chitosan has been investigated in
many forms for medical applications, and this body of work describes its progress and
development from a chitosan sponge (see Chapter 3 and Appendix 1) to the chitosan
paste (see Chapters 4 and 5).
The chitosan sponge was developed as an adjunctive therapy, local antibiotic
delivery device for musculoskeletal wound infection prevention. Numerous in vitro and
in vivo investigations have been performed to establish the sponge’s drug release,
degradation, and infection prevention properties. Prior to the scale-up fabrication and
analysis of the chitosan sponge in a larger version, a transition occurred to a new source
of chitosan material which cause a drift in previously established degradation properties.
The chitosan sponge fabricated from the new source of chitosan material was altered
using a buffering procedure to produce an acid modified, chitosan sponge version in an
attempt to regain lost degradation capabilities (Chapter 3). A large number of material
characterization tests were performed to determine how the acid modified version
affected the chitosan sponge. This work examined the effect of using 0.25 molar sodium
acetate buffers, at pH 4.6 or 5.6, to fabricate sponges with an amorphous chitosan
polymer structure. Sponges were evaluated for their crystallinity, thermal, spectroscopic,
and morphological properties, in addition to in vitro degradation, and cytocompatibility
analysis using normal human dermal fibroblasts. In vivo degradation and biocompatibility
were also examined after four and ten days in rat intramuscular tissues. Both buffered
chitosan sponge variations exhibited decreases in crystallinity and thermal decomposition
temperatures, and increases in surface porosity, which was related to an over 40%
increase in degradation over ten days in vitro from the neutral sponges. There were no
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significant differences between sponges during in vivo degradation over ten days with
respect to histomorphometric analysis of the recovered sponges. These results
demonstrated that the sodium acetate buffer did change characteristic chitosan sponge
material properties, and increasing the in vivo sponge degradation rate will require
balancing material characteristics and processing.
While further investigation into the scaled-up manufacturing of the chitosan
sponge is required, collaboration with health care professionals has led to the desire to
develop additional abilities in a chitosan, drug delivery device. The chitosan sponge
provides local drug delivery from a biodegradable and biocompatible device. Additional
benefits of injectability, for ease of application, and adhesivity, preventing the device’s
migration within the wound site, would provide more effective full wound coverage and
encourage drug diffusion to typically, hard-to-reach contaminated tissues within and
between the wound tissues.
These desired properties led to the development of the chitosan paste. The
chitosan paste’s preliminary screening proved it to be promising as a drug delivery device
with added injectability and adhesive properties. Subsequent in vitro (Chapter 4) and in
vivo (Chapter 5) analysis has shown promise for the chitosan paste device as a viable
device for antibiotic delivery to prevent infection in a musculoskeletal wound.
Preliminary in vitro screening for adhesive and drug elution properties led to the
development of the chitosan device in the formulation as described in the full in vitro
analysis (Chapter 4). Similar to the acidic buffered chitosan sponge, many of the device’s
properties will were shown initially to be affected by the amount of acid incorporated.
The paste is a composite of the powders from an acidic, ground chitosan sponge, varied
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at 0.05 and 0.15 molarity acetic acid, and neutral, ground chitosan sponge in an 80:20,
acidic to neutralized fabricated chitosan ratio. Both versions of finalized chitosan paste
devices were confirmed to have a burst release of active vancomycin and complete
degradation in a lysozyme solution in less than 72 hours in vitro. Both paste versions
were able to be ejected from a modified, tapered tip syringe, while the 80:20, 0.05 M
acetic acid to neutralized chitosan paste variation had a higher adhesive strength as
compared to the 80:20, 0.15 M acetic acid to neutralized paste version. The chitosan
paste device, when hydrated with a 5 mg/mL vancomycin solution, proved to be an
injectable, adhesive, and biocompatible drug delivery device, with potential for
application to musculoskeletal wound sites as an adjunctive therapy for infection
prevention. The results indicated that the 80:20, 0.05 M acetic acid to neutralized
chitosan paste variation had a lower acid concentration, with no significant loss of
mechanical, or drug delivery properties, and this variation was selected for further
analysis.
In preparation for in vivo, animal model testing (Chapter 5), the 80:20, 0.05 M
acetic acid to neutralized chitosan paste material was tested for cytocompatibility in vitro,
by loading the paste into a porous cell culture plate insert, which was placed into the
media, directly above cultured fibroblasts. For this biocompatibility analysis the 80:20,
0.05 M acetic acid to neutralized chitosan paste version was found not to be
cytocompatible. Subsequent screening of the full range of acidic to neutral chitosan paste
ratios showed that after 72 hours, the 50:50 paste version was the threshold ratio for
cytocompatibility in cell culture with the multiple well cell-well insert evaluation.
Biocompatible versions from the in vitro biocompatibility screening, 50:50 and 30:70
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chitosan paste variations were implanted in an intramuscular, rat, back pouch model for
in vivo biocompatibility analysis. The 50:50 paste version, when compared to the 30:70
paste version and to chitosan sponges, was found to be inflammatory in rat tissue
histological evaluations and indicated significant immune cell infiltration. In a functional
infection prevention model with a mouse catheter, biofilm infection prevention model 4
mg/mL vancomycin loaded, 50:50 chitosan paste was as effective at biofilm infection
prevention as a 4 mg/mL vancomycin loaded, neutralized chitosan sponge control.
In summary, a novel chitosan paste device, formed from the combination of acidic
and neutralized chitosan sponge derived powders, was shown to be both an injectable and
adhesive device, with potential applications as an antibiotic delivery device for adjunctive
musculoskeletal wound infection prevention therapies. The initial investigation and
optimization of degradation properties of an acid modified chitosan sponge device
(Chapter 3), led to the preliminary development and in vitro analysis of the chitosan
paste, incorporating a portion of the paste as acidic chitosan (Chapter 4). Subsequent in
vivo, animal model testing with the chitosan paste (Chapter 5) prevented a biofilm
forming bacterial infection in vivo, even though chitosan paste biocompatibility
enhancements are needed which should be resolved through further chitosan paste device
optimization.
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Chapter 3
Effects of Sodium Acetate Buffer on Chitosan Sponge Properties and In Vivo
Degradation in a Rat Intramuscular Model

Introduction
Musculoskeletal injuries are some of the most prevalent injuries in both civilian
and military populations and their infections can be difficult to treat, often resulting in
multiple surgeries, as well as increased patient morbidity, treatment time, and costs. 1 In
military operations extremity injuries are the most frequent and many involve complex,
open fractures where bone is exposed to environmental contamination. 2 Extremity
injuries are especially susceptible to multiple pathogenic, and sometimes multidrug
resistant bacteria, such as methicillin resistant Staphylococcus aureus (MRSA),
Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli.3,4 Up to 25%
of open fractures develop osteomyelitis, bone infection caused by bacteria or fungus, and
treatment failure rates are higher when either MRSA or P. aeruginosa are the infecting
organisms.5-7
The current standard of care for extremity wounds includes debridement and
irrigation of the affected area, as well as fracture stabilization, with serial debridement
and irrigation steps to follow.8 Systemic antibiotics are the current standard method of
prophylaxis and treatment for infections. Due to the avascular nature of traumatic wound
sites, delivery of inhibitory concentrations of antibiotics to affected tissue through the
bloodstream requires high dosing which carries risks ranging from allergic reaction to
ototoxicity or kidney failure.9-11 Local antibiotic delivery, used as an adjunctive therapy
to systemic dosing, can overcome the issues of sub-bactericidal antibiotic concentrations
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in the avascular zones of wound sites by providing high levels of antibiotics directly to
the injured tissues.
Two of the most commonly used local antibiotic delivery systems in clinical
practice include antibiotic-loaded polymethylmethacrylate (PMMA) and calcium sulfate
(CaSO4). Antibiotic loaded PMMA beads provide a predictable release of antibiotic for
several weeks and reduce the infection rate in severe open fractures, but disadvantages
include the possibility for surgical removal and long term, sub-inhibitory antibiotic
concentrations which may encourage antibiotic resistant bacteria strains and/or biofilm
formation on the implant’s surface.12-17 CaSO4 is a degradable material with
characteristic, high initial antibiotic burst-release in the local wound site, elevated wound
drainage, and limited antibiotic choices and dosages. 18-21
Porous chitosan sponges have been previously developed for rapid local drug
delivery as an adjunctive therapy during extremity wound debridement and irrigation. 22,23
These biocompatible sponges can be loaded at the point of care with physician selected
antibiotics and then release a high local dose of antibiotic to reduce bacterial levels. 22,23
However, one problem is that these sponges do not degrade quickly and can persist in the
wound, after the sponges have delivered the antibiotic. This delayed degradation is a
problem because remaining chitosan may act as a nidus for secondary infection.
One approach to increase chitosan degradation is to decrease crystallinity of the
chitosan polymer.24 Crystallization of the chitosan sponges occurs during sodium
hydroxide (NaOH) washes, used in the neutralization process. Using different solutions
for residual acid removal without inducing crystallization could help to increase sponge
degradation. In this investigation, sodium acetate buffers were used after a NaOH wash
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of the chitosan sponges and were compared to neutral sponges with NaOH washes only.
We hypothesized in vitro and in vivo analysis would reveal that modification of sponges
using the buffering step in fabrication would increase sponge degradation while not
affecting biocompatibility, compared to neutral chitosan sponges. The first aim of this
study was to evaluate whether the buffering procedure affected in vitro degradation and
biocompatibility, as well as thermal, crystalline, spectroscopic, and morphologic
properties. We then evaluated the in vivo degradation and biocompatibility of the
chitosan sponges in a rat dorsal muscle pouch model through both quantitative and
qualitative histological assessment of the implant sites.
Materials and Methods
Fabrication. Chitosan sponges were manufactured using previously described double
lyophilization methods.22,25,26 Chitopharm S chitosan was purchased from Chitinor AS
(Tromsoe, Norway) having a 82 ± 2 degree of deacetylation (DDA), 251 ± 17 kDa
weight-average molecular weight (MW) and 2.013 ± 0.145 polydispersity index and all
acids and buffer solutions were obtained from Fisher Scientific (Pittsburg, PA) First, the
chitosan was dissolved at 1% (w/v) in a 1% (v/v) blended acid solvent (3:1 ratio of lactic
to acetic acid). The dissolved chitosan solution was cast (250 mL) in an 11×20 cm
container, frozen at -20°C, and lyophilized in a Labconco (Kansas City, MO) FreeZone
2.5 Liter Benchtop Freeze Dry System. The dehydrated, acidic chitosan sponges were
then randomly assigned to NaOH or one of two different acetate buffer treatments to
create neutralized or buffered sponges, respectively. For the NaOH neutralization
treatment, the sponges were rinsed in 250 mL of 0.6 M NaOH for approximately seven
minutes, washed with copious amounts of ultrapure water until a neutral pH was reached,
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and then re-frozen at -20°C and re-lyophilized. To fabricate buffered sponges, the
hydrated sponge was gently compressed and then soaked in approximately 500 mL of a
0.25 M acetate buffer at either 4.6 or 5.6 pH. After 30 minutes of hydration in the buffer
solution, excess buffer solution was removed and the buffered sponge was re-frozen at 20°C and re-lyophilized. After the second lyophilization the neutral, 4.6 pH buffered and
5.6 pH buffered chitosan sponges were stored in a desiccator cabinet until subsequent
analyses.
In vitro Degradation. Degradation of neutralized, 4.6 pH, and 5.6 pH buffered chitosan
sponges was determined based on mass loss using a protocol previously reported. 26,27
Briefly, triplicate samples of each sponge formulation were trimmed to similar sizes and
weighed on a Mettler Toledo (Columbus, OH) XS205 Dual Range scale to establish an
initial weight. Samples were placed in a 125 mL Nalgene (Rochester, NY) container and
hydrated with 35 mL of 1 mg/mL 2× crystallized chicken egg white lysozyme and
penicillin (100 units/mL), streptomycin (100 mg/mL), amphotericin B (0.25 µg/mL),
both from MP Biomedicals (Solon, OH), in 1× phosphate buffered saline (PBS).
Degradation samples were placed on a rocking shaker in an incubator at 37°C and the
degradation solution was exchanged every 24 hours over 10 days. At each 24 hour
interval, three replicate chitosan sponge samples from each sponge variation were
removed from the degradation solution and rinsed in ultrapure water. Sponge samples
were then placed in a vacuum oven at 60°C for two days until dry and were weighed for a
final sponge weight. The percent remaining of the sponge was calculated using the
following equation:

( )

(

)
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(1)

The gentle, vacuum drying process eliminated the option of utilizing that individual
samples a second time, and therefore separate samples were analyzed for each replicate
and time point.
Molecular Weight. Molecular weight was determined by gel permeation
chromatography (GPC), using a TOSOH Bioscience (King of Prussia, PA) TSKgel
G5000PWxl column at 30°C, coupled with a Wyatt (Santa Barbara, CA) DAWN
HELEOS II multi-angle light scattering detector and Varian Prostar 450 refractive index
detector. Chitosan samples were dissolved at 1 mg/mL in the mobile phase solution of
0.15 M acetic acid and 0.1 M sodium acetate at pH 5. An injection volume of 50 µL and
a specific refractive index increment (dn/dc) for chitosan of 0.163 mL/g were used. 28
Crystallinity. X-ray diffraction (XRD) was used to characterize the crystal structure of
the raw chitosan material, as well as neutral, 4.6 pH, and 5.6 pH buffered chitosan
sponges. XRD patterns were determined using multiple scans from a Bruker AXS
(Madison, WI) Advanced D8 X-ray diffractometer with Kα Cu radiation source at 40 kV
and 40 mA over a 2θ range from 5° to 40° with a step size of 0.05° and a time/step of 0.2
seconds. The crystallinity index, CrI, was calculated as a relative measure of the
crystallinity of the chitosan in the sponges.28,29 The CrI was determined by taking the
difference between the maximum intensity of the characteristic chitosan diffraction peak
at 2θ = 20° and the amorphous diffraction signal at 2θ = 16° and normalizing to the 2θ =
20° diffraction peak.
Thermal Analysis. A Netzsch (Selb, Germany) 200 PC differential scanning calorimeter
(DSC) was used to evaluate the thermal properties of the three chitosan sponge
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formulations and chitosan powder (n = 3). Samples were scanned from 40 to 400°C at
20°C/min in order to assess variations in endothermic and exothermic peak temperatures
Spectral Analysis. In order to evaluate sponge differences, chitosan sponge sample
functional group chemistries were compared (n = 3) using attenuated total reflectance
Fourier transform infrared spectrometry (ATR-FTIR) with a ThermoScientific (Waltham,
MA) Nicolet iS10 FTIR spectrometer with a diamond ATR crystal. Absorbance spectra
were acquired using 64 scans with a resolution of 4 cm -1 and processed using the Thermo
Scientific OMNICTM Software Suite.
Morphology. Surface morphology of the three chitosan sponge formulations (n = 3) was
assessed using a FEI/Philips XL30 Environmental Scanning Electron Microscope at
15kV and samples sputter-coated with 30 nm of Au/Pd. Images were visually inspected
for differences between sponge groups such as surface texture and porosity.
Direct Contact Biocompatibility. A protocol modified from ASTM F813-07 “Standard
Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices”
was followed in order to assess the direct contact biocompatibility between the chitosan
sponge variations and normal human dermal fibroblasts (NHDF) purchased from Lonza
(Walkersville, MD). NHDF cells (passages 4 through 6) were seeded at 6×10 4 cells/mL
and allowed proliferate to confluence on BD Falcon (Franklin Lake, NJ) 12-well
polystyrene tissue culture plates in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/mL),
streptomycin (100 mg/mL),amphotericin B (0.25 µg/mL), all purchased from Fisher
Scientific, under standard cell culture conditions (37°C and 5% CO2 atmosphere). Cell
culture medium was aspirated and refreshed with 1 mL of fresh medium before a single 8
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mm diameter test specimen (n = 5) of either a neutralized chitosan sponge, 4.6 pH
buffered chitosan sponge, 5.6 pH buffered chitosan sponge or a polyurethane sponge
(control) was gently placed in a well in direct contact with the cell monolayer. Cultures
were incubated for either one or three days before biocompatibility was assessed with the
Cell Titer-Glo® Luminescent Cell Viability assay (Promega, Madison, WI).The
luminescent signal, which corresponded to the amount of adenosine triphosphate and the
number of viable cells through a standard dilution of known concentrations of cells, was
recorded at 590 nm using a BioTek (Winooski, VT) FLx-800 Fluorescence Microplate
Reader.
In vivo Degradation. A total of 23, three month old male Sprague-Dawley rats (average
weight of 398 g) were utilized for this study. This pre-clinical study was approved by
institutional review boards at the University of Memphis (IACUC protocol #0720) and
the Army Medical Research and Material Command (Protocol DM 090455.02) and
followed guidelines set forth by both organizations. Rats were anesthetized with 2%
isoflurane in an environmental chamber and given a sub-cutaneous injection of carprofen
in the rat flank. The rat was prepared for sterile surgery with anesthesia maintained using
4 to 5% isoflurane. Two 1.5 cm incisions were made through the skin on each side of the
midline (4 incisions total). In each incision, a 1.25 cm pouch was created in the latissimus
dorsi muscle. One disc shaped implant, 9.5 mm in diameter and approximately 5 mm
thick, was implanted bilaterally in each muscle pouch. Test groups included gamma
irradiation sterilized (25.0 to 40.0 kGy dosage) neutralized chitosan sponge, 4.6 pH
buffered chitosan sponge, 5.6 pH buffered chitosan sponge and an absorbable gelatin
sponge (Gelfoam®, Pfizer, New York City, NY) as a positive control. Each rat received
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one of each implant, randomized among the four incision sites. After implantation, the
muscle incision was sutured while the skin was closed with one to three staples.
Carprofen was also administered for two days post-operatively. Ten rats were sacrificed
at the 4 and 10 day time points (n = 10). Satellite animals were sacrificed at the 14, 21
and 28 day time points (n = 1) for preliminary investigation of prolonged degradation.
Satellite animal degradation data was used for selecting degradation time points for future
in vivo studies. After each sacrifice the implanted region and surrounding tissue were
excised (see Figure 5A) and placed in 10% phosphate buffered formalin for two days.
Tissue sections were then bisected across the implant for quantitative and qualitative
histological evaluation (paraffin-embedded and H&E stained). The percentages of sponge
and fibrous tissue in the defect area of the stained tissue sections were measured and
calculated using a Nikon inverted microscope Eclipse TE300 and BIOQUANT® OSTEO
II image analysis software, and cellular response was graded by three blinded reviewers.
Statistical Analysis. In vitro degradation testing was analyzed by least squares
regression. Thermal analysis was analyzed using one-way ANOVA with Tukey’s post
hoc analysis. In vitro biocompatibility samples were compared using an independent, two
sample t-test. Statistical analyses on the histological results were performed initially with
ANOVA and Holm Sidak post hoc analysis was used for the percent of fibrous tissue in
the defect and tissue response. Statistical significance level was set at α = 0.05.
Results
In vitro degradation. The percentage of sponge remaining over time in the in vitro
degradation study is shown in Figure 1. Both the pH 4.6 and 5.6 buffered chitosan sponge
formulations exhibited significantly increased degradation, 71 and 44% respectively, over
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the neutral chitosan sponge. Although the pH 4.6 buffered chitosan sponge had a lower
percentage of sponge remaining, there was no significant difference between the pH 4.6
and pH 5.6 sponge (p = 0.087). There was a significant decrease over time for the 4.6 pH
buffered chitosan sponge (p = 0.0001) and 5.6 pH buffered chitosan sponge (p = 0.024)
groups, but there was no change over time for the neutral sponge group (p = 0.592).
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Figure 1. Results for the enzymatic-mediated degradation of neutral (♦), pH 5.6 buffered (▲), and pH 4.6
buffered () chitosan sponges represented as mean ± standard deviation for the percent by weight of the
chitosan sponge remaining over time (n = 3).

Molecular Weight, Crystallinity, and Thermal Analysis. The initial molecular weight,
crystallinity, and thermal analysis of chitosan powder and neutralized and buffered
chitosan sponges is shown in Table 1. XRD analysis results (Table 1) for the crystallinity
index reveal a difference between the chitosan powder and neutralized chitosan sponge.
Spectra (Figure 2) reveal characteristic diffraction peaks for chitosan powder at 2θ of
20

10.5° and 20°. After manufacturing the powder into a neutralized chitosan sponge, the 2θ
of 20° peak is reduced to a minimum and subsequent manufacturing into both buffered
sponge versions eliminated this peak altogether. The 2θ = 10.5° diffraction peak intensity
varied between the sponge groups, but all of the group’s 2θ = 10.5° peak were lower than
the chitosan powder’s.

Analysis of DSC data for the chitosan samples revealed that endothermic and
exothermic peaks appeared at 105-111°C and 291-326°C, respectively (Table 1). The
endothermic peak corresponds to water loss and the exothermic peak can be attributed to
polymer decomposition, possibly of amine units.29-31 The chitosan powder exhibited the
highest exothermic peak temperature; after processing chitosan into a neutral sponge, the
exothermic peak temperature decreased (p < 0.001). Buffering the chitosan sponges at pH
5.6 and 4.6 lowered the exothermic peak temperature by 23.4 and 30.2°C, respectively,
from the neutral chitosan sponge’s peak temperature (p < 0.001).
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Figure 2. Stacked x-ray diffraction (XRD) spectra in the 2θ range from 5° to 40°of (top to bottom) the
chitosan powder, neutral chitosan sponge, pH 5.6 buffered chitosan sponge, and pH 4.6 buffered chitosan
sponge.

Spectral Analysis. As shown in Figure 3, several peaks characteristic of chitosan were
identified at the following wavenumbers: H-bonded, O-H stretching at the broad peak
centralized at 3350 cm-1; alkane, C-H stretching vibrations at 2910 and 2850 cm-1; amide
I band C=O stretching at 1640 cm-1; amine and amide II band N-H bending at 1550 cm-1;
C-H rocking at and just below 1400 cm-1; ether group C-O stretching at 1010 cm-1. All
peaks present are typical to chitosan functional groups and buffered groups showed
increased peak intensities and peaks shifting downward, indicative of acetate’s presence
in these sponges.
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Figure 3. Stacked and averaged (n = 3) ATR-FTIR absorbance spectra for chitosan powder, and neutral, pH
5.6 buffered and pH 4.6 buffered chitosan sponges.

Morphology. The morphology of the chitosan powder before processing into sponges
can be seen in Figure 4A, while the surface of the neutral, pH 5.6 and pH 4.6 buffered
chitosan sponges can be seen in Figures 4B, C, and D, respectively. Upon inspection, the
surfaces of both buffered chitosan sponge appear to have greater porosity than the neutral
sponge. The morphology of both the pH 5.6 and 4.6 buffered chitosan sponges appears
similar.
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Figure 4. Scanning electron microscopy representative images of chitosan powder at 30× magnification (A)
as well as the surface structure of the laminar sheets that comprise the neutral (B), pH 5.6 buffered (C), and
pH 4.6 buffered (D) chitosan sponges.

Direct contact biocompatibility. When normalized to the polyurethane sponge control
(Figure 5), each type of chitosan sponge caused significant decreases in biocompatibility
after one day of direct contact treatment (p ≤ 0.041). However, after the three day
treatment end point, there were no significant differences between the sponge groups and
the control. Additionally, there was no cellular malformation, degeneration, sloughing, or
lysis and no reduction of the cell layer at the specimen perimeter upon microscopic
examination at either time point.
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Figure 5. A graph of cell number after normal human dermal fibroblast direct contact cell viability testing
of neutral, pH 5.6 buffered and pH 4.6 buffered chitosan sponges after 1 and 3 days, analyzed using Cell
Titer-Glo Luminescent Cell Viability Assay. (n = 5, * represents p < 0.05 versus polyurethane sponge
control)

In vivo degradation. Representative images from the in vivo degradation study are
shown in Figure 6, where Figure 6A shows an implanted sponge in a rat and Figure 6B
shows a bisected tissue block before histological processing. Histological evaluation of
the tissue revealed some implants to be completely degraded, (Figure 6C) while others
remained more intact (Figure 6D-F). The quantitative evaluation of the tissue histology
for the percentage of implant area per defect area is shown in Figure 7. After 4 and 10
days of sponge implantation in the back muscle pouches of rats, none of the experimental
groups, with regard to time and sponge type, exhibited significant differences in percent
of implant area per defect area (p = 0.0856). Although not statistically different, all three
types of chitosan sponge had 5.1-5.6% and 0.3-1.6% lower average percentage of implant
in the defect after 4 and 10 days than the control gelatin sponges.
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Figure 6. This image set depicts the surgery site and sponge retrieval (A), a bisected tissue section prepared
for histological analysis (B), as well as representative H&E stained tissue sections of the control gelatin
(C), neutral chitosan (D), pH 5.6 buffered chitosan (E) and pH 4.6 buffered chitosan sponge (F) surgery
sites.

Figure 7. A histological analysis boxplot of the percent of gelatin, neutral chitosan, pH 5.6 buffered
chitosan and pH 4.6 buffered chitosan sponge implants remaining in the defect area, 4 and 10 days after
surgery. ( represents a data point outside of the standard deviation)
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Both qualitative and quantitative evaluation of the fibrous tissue present around the
implants revealed a wide variability in fibrous tissue response between surgical sites.
After 10 days of implantation, the pH 5.6 buffered sponges exhibited a 37.08% increase
in fibrous tissue present in the defect (Figure 8) over the control gelatin sponges (p =
0.003).
The only chitosan sponge type which demonstrated complete degradation in vivo
was the pH 4.6 buffered chitosan sponge (n = 1) after the satellite time point of 21 days
implantation (Table 2). The pH 4.6 buffered chitosan sponge was present after 28 days of
implantation in a different satellite animal, with 17.28% implant in the defect. There was
no percent implant data for the pH 4.6 and 5.6 buffered chitosan sponges at days 14, 14
and 21, respectively as they may have been lost in histological processing. Based on
similar photographs and tissue histology, the gelatin sponge is believed to have
completely degraded after 28 days of implantation.
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Figure 8. A histological analysis boxplot of the percent of fibrous tissue present in the defect area for
gelatin, neutral chitosan, pH 5.6 buffered chitosan and pH 4.6 buffered chitosan sponge implants, 4 and 10
days after surgery. (* represents p < 0.05 versus each other,  represents a data point outside of the standard
deviation)
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After 4 days, tissue inflammatory response from the pH 5.6 and pH 4.6 buffered
chitosan sponges was significantly higher than the tissue response from gelatin sponges
(p = 0.029 and p < 0.001, Figure 9). After 10 days of implantation, tissue response was an
average of 1.98 to 2.11 grades lower from gelatin sponges than from all three types of
chitosan sponges (p < 0.001). Cellular response was not significantly different between
chitosan sponges, either neutral or buffered, at either time point. However, a highly
variable response was observed for all three histophotometry measures: percentage
implant, fibrous tissue, and tissue response grade.

Figure 9. A histological analysis boxplot of the graded inflammatory response to the gelatin, neutral
chitosan, pH 5.6 buffered chitosan and pH 4.6 buffered chitosan sponge implants, 4 and 10 days after
surgery. Individual histological sections were scored (using increments of 0.25) where 0 indicated a
missing or minimal implant and minimal response, 1‒2 indicated mild leukocyte density, 2‒3 indicated a
slightly elevated response around the implant, 3‒4 indicated a moderate cell response, and 4‒5 indicated a
high cell density in and around the implant. (* represents p < 0.05 versus each other at each time point, 
represents a data point outside of the standard deviation)
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Discussion
Our results show that the incorporation of a sodium acetate buffer into a chitosan
sponge manufacturing process does significantly affect sponge material properties,
especially increasing in vitro degradation; however, it does not affect in vitro or in vivo
biocompatibility or in vivo degradation in rat intramuscular tissue. Evidence that the
buffer affects in vitro sponge degradation is that both buffered sponge formulations
degraded significantly in mass, with 18-61% sponge remaining, compared to the neutral
sponge, with 97-100% remaining. The buffering process at pH 4.6 reduced the sponge’s
molecular weight by 0.5%, compared to the neutralized sponge. Although not significant
this decrease is important because the literature indicates that in vivo degradation is
directly proportional to its molecular weight.32,33 While a decrease in molecular weight
was found in the chitosan sponges from the powder, no large differences were seen
between all three chitosan sponge types.
Chitosan’s DDA and crystallinity have both been previously shown to be
inversely proportional to chitosan’s degradation in vitro.34,35 Similar to other reported
findings,29 crystallinity analysis of the neutral and buffered sponges indicated that our
manufacturing, specifically the lyophilization process, decreased crystallinity from the
initial chitosan powder.
Thermal analysis of the chitosan powder and sponges indicated that the chitosan
lyophilization and neutralization procedure decreased exothermic peak temperatures,
corresponding to amine decomposition.31 The exothermic peak temperature decreased by
7.3-9.4% upon the addition of the buffering step which may correspond to a decrease in
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molecular weight from chitosan powder, a relationship shown in other investigations, 30,36
similar to our findings of decreased sponge molecular weight and crystallinity.
Our chemical analysis confirmed the various standard absorbance peaks of
chitosan were present in the sponges,37 along with the presence of acetate functional
groups in the buffered sponges as seen in other similar investigations. 38,39 Although
another researcher has reported the appearance of a carboxylic acid peak from chitosan at
approximately 1750 cm-1, Nunthanid et al did not see this carboxylic acid peak in either
chitosan flakes or chitosan acetate which corroborates our findings. 38
Morphological differences were seen in surface SEM images of the neutral and
buffered chitosan sponges. The apparent increase in surface porosity of both buffered
chitosan sponges, as compared to the neutral sponge, may be the physical manifestation
of changes in the chitosan’s molecular weight and crystallinity, and therefore may also be
related to an increase in in vitro degradation. Other studies of composite acid films
similarly produced increased surface roughness with increased acid incorporation in
chitosan films.40 Both buffered sponges exhibited similar morphology, indicating little
effect of the buffer’s pH on surface morphology. The similarities in chitosan sponge edge
and corner morphology of the neutral and buffered chitosan sponges indicate that all of
the sponges have a similar internal layering of chitosan layers, an example of which may
be seen in a previous publication.25
A review of the literature indicates that higher DDAs and molecular weight both
improve cytocompatibility and cell attachment. 41 All of the chitosan sponges exhibited
similar molecular weights and hence similar in vitro cell response. While cellular
compatibility levels in the literature fluctuate in direct contact assays largely due to the
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positive control selection and exposure time, our results show similar fluctuations over
time to those found for other chitosan materials and applications. 26,42
Chitosan is reported to be biocompatible and biodegradable,41 however there have
been few studies performed using chitosan with only minimal modifications such as the
buffer procedure, administered by routes other than orally, for assessing biodegradation
and biocompatibility. In those studies that have been reported, chitosan in vivo
degradation is described as being dependent on molecular weight,43 and becomes
localized in the liver after intravenous injections.44 In other studies, chitosan has been
reported as having minimal degradation after subcutaneous implantation,45 or rapid
degradation after use as a wound dressing.23 These disparate findings led us to develop
this screening animal model as an evaluation method for our chitosan sponge device.
There was a wide variation in results, which lead to neither the neutral nor buffered
chitosan sponges showing significant differences in percentage of implant in defect from
the gelatin sponges, which served as a positive control of degradation. While there was
wide variability in the percent implant in defect of the gelatin sponges, more of the
gelatin sponges completely degraded than the chitosan sponges, confirming that sponge
degradation could be determined with this animal model.
Chitosan sponges exhibited statistically similar inflammatory tissue responses, but
there was an increase in inflammatory response in the pH 4.6 buffered sponges at day 4,
as compared to the pH 5.6 buffered chitosan sponges. However, this inflammatory
response difference narrowed at day 10 of implantation. The buffer pH reduction could
be causing a slightly more acute inflammatory response in the rat muscle tissue. This
result is similar to the moderate inflammatory response observed in an in vivo study with
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Sprague-Dawley rats of chitosan coated, via silane-gluteraldehyde linkage, to titanium
with histological images seemingly comparable to inflammatory responses as seen caused
by the chitosan sponges.46
Although there were no significant differences in percent implant in the defect
between the chitosan sponges after 10 days, which was a surprising finding in
comparison to the time course of the in vitro study, a few key differences could be seen in
the satellite animals (days 14, 21, and 28). Because the pH 4.6 buffered chitosan sponges
completely degraded after 21 days of implantation, this time point seems to be a more
realistic estimate of the time course of complete in vivo degradation. However, this
degradation time may not be ideal because the chitosan sponges typically release most of
the loaded antibiotics early.22
The available chitosan literature does not report many details on in vivo chitosan
degradation, and the in vivo degradation and elimination mechanism is still not well
understood. In the literature, there is molecular weight dependence for timely in vivo
degradation and elimination, while an increase in DDA and molecular weight may
provide for better biocompatibility.34,47,48 Our results indicate that the modified chitosan
sponge is biocompatible and is degrading in this screening model. From the chitosan
literature, the determination and achieving a desired in vivo degradation rate will require
balancing between the chitosan’s molecular weight, DDA, crystallinity, and the applied
manufacturing methods. Future work is needed and planned to define the in vivo
degradation profile of current chitosan sponge devices over an extended period of time so
that the further development of the chitosan sponge may provide an alternative option for
the adjunctive therapy of contaminated musculoskeletal wounds.
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Chapter 4
Fabrication and In Vitro Evaluation of Chitosan Paste as a Potential Injectable and
Adhesive Local Antibiotic Delivery Device

Introduction
Musculoskeletal wounds are common in battlefield and civilian, clinical
environments.1,2 Large, open, soft tissue and bone injuries are highly likely to be
contaminated which may develop into life threatening complications. 3-5 After lifesaving
stabilization of patients with open, musculoskeletal wounds, surgical intervention through
debridement and irrigation along with systemic antibiotics are the gold standard
treatments.3,6 Contaminating bacteria in these wound sites may not be prevented from
establishing infections due to poor systemic antibiotic diffusion through the blood supply
to the vascular compromised tissue at the wound site. 7,8 To prevent and combat bacterial
infections in musculoskeletal wounds, our laboratory has fabricated and evaluated an
adhesive and injectable chitosan paste device intended for adjunctive therapy to
musculoskeletal wounds after initial lifesaving or surgical treatment.
The chitosan paste device was fabricated using a combination of dehydrated,
finely ground, mildly acidic and neutralized chitosan products. Simple hydration of the
combined chitosan products with an antibiotic solution yields a viscous paste that is
designed to be injectable through a taper tip syringe for ease of application, 9 and able to
adhere to applied musculoskeletal tissues and stabilization devices. After the release of
any antibiotics loaded, the chitosan paste device should also biodegrade into its
compatible products.10
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Chitosan is a naturally occurring, linear polysaccharide and cationic weak base
soluble in dilute weak acids and in many forms, characterized as biodegradable,
antibacterial and able to store and release drugs. 10-12 The acidity and pH of chitosan
devices play a role in their functionality.13,14 Preliminary screening analysis of the
developed chitosan paste variations have enabled some narrowing of the chitosan
variables, such as degree of deacetylation, molecular weight and hydration rate for the
chitosan paste down to what was initially selected for these selected analyses, where the
paste’s acid concentration effects were analyzed at two different variations.
The objective of the present investigation was to investigate which of the chitosan
paste variations, with a focus on acetic acid concentrations differences, would produce
desired injectable and adhesive properties for the drug delivery, degradable and non-toxic
device. The paste fabrication and testing procedures are outlined in Figure 1. Fabricated
chitosan products were characterized individually for differences in morphology,
crystallinity and molecular functional groups which, because of their relationship to
degradation and biocompatibility, should be indicative of chitosan’s in vivo behavior.
Additional functionality evaluations of the two final chitosan paste device versions for
acid concentration, absorbency, injectability, adhesivity, degradability as well as
antibiotic elution, activity and cytocompatibility provided and in vitro assessment of the
chitosan paste’s in vivo functionality.
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Figure 1. A flow chart summarizing the experimental approach. Chitosan products from the fabrication
processes are first characterized and compared, followed by the functionality analysis and comparison of
the final chitosan paste device variations.
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Materials and Methods
Fabrication. The chitosan paste was fabricated using Chitopharm S chitosan powder
from Chitinor AS (Haugesund, Norway) with an 82 ± 2 degree of deacetylation (DDA),
251 ± 17 kDa weight-average molecular weight (MW) and 2.013 ± 0.145 polydispersity
index. The chitosan was dissolved at 1 % w/v in acetic acid at either 0.05 molar (M) or
0.15 M in ultrapure water. In an 11×20 cm plastic container, 333 mL of acidic, dissolved
chitosan solution was cast, frozen at -20 °C, and subsequently lyophilized. Additional
lyophilized chitosan, made using 0.15 M acetic acid, was neutralized in 0.6 M sodium
hydroxide (NaOH) and washed with copious amounts (> 6 L) of ultrapure water. These
neutralized, hydrated sponges were frozen at -20°C and lyophilized a second time.
Fabrication procedures yielded three forms of dehydrated chitosan products to this point:
(1) a twice lyophilized and neutralized chitosan, (2) a 0.05 M acetic acid, lyophilized
chitosan, and (3) a 0.15 M acetic acid, lyophilized chitosan. Each of these lyophilized
chitosan products were physically ground into a powder, with flake sizes ≤ 0.5 mm
diameter (see Figure 2) using a blade grinder, and combined to create two chitosan paste
test variations: (1) one with an 80:20 ratio of 0.05 M acetic acid to neutralized chitosan,
(2) and a second with an 80:20 ratio of 0.15 M acetic acid to neutralized chitosan. For
application, dehydrated chitosan paste was hydrated using a 1× phosphate buffered saline
(PBS), in ultrapure water solution at 7.5 times the paste’s dehydrated weight.
Material Characterization. Used in combination to form the final paste device, the
dehydrated chitosan products were tested for visual and chemical characteristics
included: chitosan powder material, double lyophilized, neutralized chitosan product,
0.05 M acetic acid chitosan product, and 0.15 M acetic acid chitosan product.
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Surface morphology of the dehydrated chitosan products were assessed using
images from a FEI/Philips XL30 Environmental Scanning Electron Microscope
(Eindhoven, Netherlands), SEM, at 15 kV and samples sputter-coated with 30 nm of
Au/Pd (n = 3). Samples were analyzed visually for changes in appearance, such as
surface texture, as an indication of altered material properties.
Crystalline properties of the chitosan products were determined from X-ray
diffraction (XRD) spectra using multiple scans from a Bruker AXS Advanced D8 X-ray
diffractometer (Madison, WI) with Kα Cu radiation source at 40 kV and 40 mA over a 2θ
range from 5° to 40° with a step size of 0.05° and a time/step of 0.2 sec (n = 1). Relative
changes in spectra peak intensities were analyzed as an indication of changes in
crystallinity.
Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR)
spectra of the chitosan products were obtained using a ThermoScientific (Waltham, MA)
Nicolet iS10 FTIR spectrometer with a diamond ATR crystal in transmittance mode (60
scans, 4000–800 cm-1 range, 4 cm-1 resolution, n = 3). FTIR spectra peaks were analyzed
for the presence and changes in functional groups as an indication of alterations in
chitosan chemical composition.
Paste Functionality. The finalized chitosan paste device versions, which were made
using combinations of the earlier characterized chitosan products, that were functionally
tested include: 80:20, 0.05 M acetic acid to neutralized chitosan paste and 80:20, 0.15 M
acetic acid to neutralized chitosan paste versions.
To determine the final acetic acid concentration of the hydrated chitosan paste
device versions, an acid-base titration was performed (n = 3) using 0.1 M NaOH and a
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pH combination electrode. The device’s final acetic acid concentration was determined
by finding the moles of NaOH used to reach the titration’s equivalence point, converting
to moles of acetic acid using the molar ratio and dividing by the initial volume of
chitosan paste sample.
The absorbency of chitosan paste device versions was evaluated by immersing the
dehydrated paste in an excess volume of PBS at 20 °C and then removing the hydrated,
swollen paste from the unabsorbed solution using a 180 µm nylon cloth (n = 3). The
hydrated paste was weighed and rehydrated again until a consistent weight value was
obtained (approximately 20 minutes). The maximum absorbency for the paste versions
was calculated by dividing the weight of the chitosan paste at maximum hydration by the
dehydrated paste weight and the ratio is expressed in multiples of the dehydrated
sample’s weight, or “times its own weight”.
The ability of the hydrated chitosan paste device versions to be loaded and ejected
through a syringe was determined by loading 25 mL of the chitosan paste sample into a
50 cc taper tip syringe from McMaster-Carr (Atlanta, GA) with a modified, 3.80 mm
diameter tip opening (n = 3). The syringe was then fixed into an Instron (Norwood, MA)
33R, model 4465 Universal Testing Machine with a 500 N load cell, automated by
Instron’s Bluehill 2 (v2.13) software. The syringe plunger was compressed to eject the
total volume of paste from the syringe at a rate of 15 mm/sec and the maximum ejection
force was recorded. Maximum ejection forces were compared to a clinically relevant
ejection force of 330 N, which was the force threshold where an individual could no
longer eject the material from the syringe. 15,16
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Adhesive strength of the chitosan paste device versions was quantified using a
protocol modified from ASTM D4541-09e1 and D5179-02 as well as previous work (n =
9).17 Fixtures were machined so that 5 mL of the hydrated chitosan paste was adhered to
the lower platform of the universal testing machine while the upper crosshead griped an
ultra-high-molecular-weight-polyethylene cylinder with a diameter of 38.1 mm. The flat
surface of the polyethylene cylinder was lowered onto the hydrated chitosan paste
sample, 2 mm from the lower platform. The upper crosshead was then reversed at 50
mm/sec to measure the maximum force required to pull off the polyethylene cylinder
from the chitosan paste. Maximum force was then converted into adhesive strength (kPa).
The enzymatic degradation profile of the chitosan paste device versions was
analyzed by weight reduction over time (n = 5). Initial weights for dehydrated chitosan
paste samples were recorded and then samples were hydrated and placed inside a porous,
metal, hemispherical container (pore size diameter approximately 1.5 mm). The
hemispherical sample container was then completely immersed in a 125 mL plastic
container and filled with 50 mL of 1 mg/mL chicken egg white lysozyme in ultrapure
water. These degradation samples were placed on a shaker in an incubator at 37 °C and
the lysozyme solution was completely replaced at three hour intervals until degraded
paste samples were no longer recovered (30 hours). At each three hour interval, degraded
chitosan paste samples were removed from the lysozyme solution and sample container,
and the samples were dried in a vacuum oven at 80 °C for two days and weighed. The
percent remaining of the chitosan paste sample was calculated by dividing this final or
degraded paste weight by the initial paste weight and multiplying by 100%. This drying
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process was destructive to the paste samples, therefore new samples were analyzed for
each replicate at each time point.
The vancomycin concentration release profiles from the chitosan paste device
versions were determined over three days by high performance liquid chromatography
(HPLC) analysis (n = 5). Initial weights for dehydrated chitosan paste samples were
established using a scale. Chitosan paste samples were hydrated the appropriate volume
of 5 mg/mL vancomycin in PBS and placed inside a porous, metal, hemispherical
container. The hemispherical container was then placed into a 125 mL Nalgene container
and filled with 75 mL of PBS. Elution samples were placed on a shaker in an incubator at
37 °C and samples were taken at 1, 3, 6, 12, 24, 48 and 72 hour time points with
complete PBS solution replacement at each time point. Multiple samples were taken and
frozen for HPLC, antibiotic activity and biocompatibility analyses. Prior to HPLC
analysis samples were diluted by 10% with 4 M NaOH to precipitate dissolved chitosan,
which was centrifuged and excluded from the sample. HPLC analysis of eluate
vancomycin concentrations was performed using a reversed-phase C18 column with a
mobile phase of 30% acetonitrile and 70%, 0.1 M phosphate buffer at 3 pH.18 With a
flow rate of 1.4 mL/min and UV detection at 250 nm, vancomycin had a 1.5 minute
retention time.
The antibiotic activity of the chitosan paste device variation’s eluate samples
containing vancomycin were analyzed using disk diffusion, or zone of inhibition (ZOI),
methods.19 Blank disks, 6 mm diameter, hydrated with 20 µL of selected chitosan paste
eluate samples were placed on trypticase soy broth (TSB) agar plates with a cultured
lawn of Staphylococcus aureus (S. aureus) Cowan I strain. Zone of inhibition analysis
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was performed using eluate samples (n = 1 through 3) from both chitosan paste device
versions as well as with non-antibiotic loaded eluate samples from and additionally
preformed elution study as a control for dissolved chitosan. After 24 hours incubation at
37 °C, pictures were taken of the agar plates and the diameter of the ZOI, without the
disk diameter, was measured. Additionally, the chitosan paste device versions hydrated
with either 5 mg/mL vancomycin or PBS alone were filled into rings (6.6 mm diameter,
4.3 mm height) and placed in direct contact, on top of the TSA agar plates containing a
lawn of S. aureus (n = 3).
The cytocompatibility of host normal human dermal fibroblasts (NHDF) cells,
treated with the chitosan paste variation’s elution samples was evaluated using the
Promega (Madison, WI) Cell Titer-Glo Luminescent Cell Viability assay. Host NHDF
cells (passages 4 through 6) were seeded at 4×104 cells/cm2 onto transparent 96-well
polystyrene tissue culture plates in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum and 1× Penicillin-StreptomycinAmphotericin B under standard cell culture conditions (37°C and 5% CO2 atmosphere).
Host NHDF cells were treated with a 1:1 ratio of eluate sample to cell culture medium
while control host NHDF cells were treated with a 1:1 ratio of PBS to cell culture
medium. Cultures were incubated for one and three days before the Cell Titer-Glo assay
was used to determine the number of viable, metabolically active, host NHDF cells. The
luminescent signal from the assay corresponds to the adenosine triphosphate amount and
the viable cell number, through a calibration plate, was recorded at 590 nm using a
fluorescence microplate reader.
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Statistical Analysis. Significant differences were found when comparing multiple groups
in enzymatic degradation, antibiotic elution, antibiotic activity, and eluate toxicity
evaluations by using two-way analysis of variance with Tukey’s post hoc analysis. An
appropriate t-test was used when comparing between among two groups in the acid
concentration, absorbency, injectability and adhesivity evaluations. All assumptions for
normality were met and significance was indicated when p < 0.05.
Results
Material Characterization. As seen in Figure 2, the Chitopharm S chitosan powder
material (A) is composed of relatively thin and flat flakes of similar size. The chitosan
powder (A) also has relatively increased, rough surface texture as compared to the other
fabricated chitosan products (B – D), which all additionally have fibrillar-like structures
unevenly distributed across the surfaces of the flakes. The fabricated chitosan products (B
– D) all have generally larger flakes with a larger size range.

Figure 2. Representative scanning electron microscopy (SEM) images of dehydrated chitosan products at
30× magnification (scale bar represents 1 mm): (A) chitosan powder material, (B) double lyophilized,
neutralized chitosan product, (C) 0.05 M acetic acid chitosan product, (D) 0.15 M acetic acid chitosan
product.
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Chitosan’s characteristic crystalline XRD peaks are seen in Figure 3, at
approximately 2θ = 11.5° and 20° in the chitosan powder material (A). The 2θ = 20° peak
present in the chitosan powder material (A) disappears in the fabricated chitosan products
(B – D). The 2θ = 11.5° peak intensity is highest in the chitosan powder material (A), is
decreased similarly in the two acetic acid chitosan products (C and D), and decreased
even lower in the double lyophilized, neutralized chitosan product (B).
ATR-FTIR spectra, Figure 4, for both the chitosan powder material (A) and the
neutralized chitosan product (B) revealed similar characteristic chitosan peaks: Hbonded, O-H stretching at the broad, 3350 cm-1 peak; amide I band C=O stretching at
1640 cm-1; amine and amide II band N-H bending at 1550 cm-1; C-H rocking at and just
below 1400 cm-1; ether group C-O stretching at 1010 cm-1. The peaks at 1525 cm-1 and
1400 cm-1 in the two acetic acid chitosan products (C and D) revealed increased peak
intensities and peaks shifting downward, both indicative of acetate’s carboxyl group’s
presence in these products.

Figure 3. X-ray diffraction (XRD) spectra in the 2θ range from 5° to 25°of dehydrated chitosan products:
(A) chitosan powder material, (B) double lyophilized, neutralized chitosan product, (C) 0.05 M acetic acid
chitosan product, (D) 0.15 M acetic acid chitosan product.
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Figure 4. Stacked and averaged attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectra
in the 4000‒800 cm-1 wavenumber range for dehydrated chitosan products (n = 3): (A) chitosan powder
material, (B) double lyophilized, neutralized chitosan product, (C) 0.05 M acetic acid chitosan product, (D)
0.15 M acetic acid chitosan product.

Paste Functionality. As shown in Table 1, the 80:20, 0.15 M acetic acid to neutralized
chitosan paste version had a higher final chitosan paste acid concentration, a higher
maximum absorption, a lower maximum ejection force needed for injection and a lower
adhesive strength in comparison to the 80:20, 0.05 M acetic acid to neutralized chitosan
paste version. Additional injectability testing also revealed that maximum ejection forces
for both the chitosan paste device samples were higher than the maximum ejection force
for the empty syringe (6 ± 0.2 N) but were also both lower than the 330 N clinically
relevant injection force.15
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Figure 5. The degradation profile for the 80:20, 0.05 M acetic acid to neutralized chitosan paste and 80:20,
0.05 M acetic acid to neutralized chitosan paste device versions (n = 5). Percent cell viability results are
presented as the average ± the standard deviation.

Both chitosan paste device versions trended towards an increased degradation
over time as shown in Figure 5. At every time point except for the first, 3 hour time point,
there was less 80:20, 0.15 M acetic acid to neutralized chitosan paste version remaining
as compared to the 80:20, 0.05 M acetic acid to neutralized chitosan paste version.
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The 80:20, 0.05 M acetic acid to neutralized chitosan paste version exhibited a
decrease in vancomycin eluted after the 1 hour time point (see Figure 6) while the 80:20,
0.15 M acetic acid to neutralized chitosan paste version had a decrease in vancomycin
after the 3 hour time point. Both versions showed a moderate burst release with
concentrations quickly decreasing at later time points.

Figure 6. The vancomycin release profile for the 80:20, 0.05 M acetic acid to neutralized chitosan paste and
80:20, 0.05 M acetic acid to neutralized chitosan paste device versions (n = 5). Vancomycin concentration
per grams of chitosan results are presented as the average ± the standard deviation.
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Eluates from both the .05M and 0.15M acetic acid versions of the chitosan paste
loaded with vancomycin were active against S. aureus at 1, 3, 6, 12, and 24 hours (Table
2). The 80:20, 0.05 M acetic acid to neutralized chitosan paste variation eluent sample
remained active at 48 hours however, all other samples fell below vancomycin’s
minimum inhibitory concentration, 0.5 µg/mL, for S. aureus. Both chitosan paste device
versions hydrated with 5 mg/mL vancomycin exhibited antibacterial activity after 24
hours as indicated by clear zones of inhibition whereas the PBS loaded chitosan paste
device versions indicated no zone of inhibition (Figure 7).
The two chitosan paste device versions also experienced decreases in cell
viabilities after 24 hour treatment with early time points from the chitosan paste,
vancomycin elution samples (Figure 8). The two paste versions showed a rebound effect
after 72 hours of sample incubation, and all of the decreases in host NHDF cell viability
against the eluent samples, except for one time point sample, were resolved to being
cytocompatible.
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Figure 7. Representative antibiotic activity photographs for the zones of inhibition (ZOI) from chitosan
paste samples against Staphylococcus aureus. For eluate sample ZOI, (A) is a representative image of
eluate samples from the 1 hour time point group while (B) is a representative image of eluate samples from
the 72 hour time point group. The disk layout for the eluate sample ZOI studies are: top – 80:20, 0.05 M
acetic acid to neutralized chitosan paste eluate samples, bottom – 80:20, 0.15 M acetic acid to neutralized
chitosan paste eluate samples, right – 80:20, 0.05 M acetic acid to neutralized chitosan paste control
samples, left – 80:20, 0.15 M acetic acid to neutralized chitosan paste control samples. Chitosan paste
samples shown in (C) and (D) are 80:20, 0.05 M acetic acid to neutralized chitosan paste samples placed
directly on top of the agar plate where (C) has been loaded with 5 mg/mL vancomycin and (D) has been
loaded with PBS alone; (E) and (F) are 80:20, 0.05 M acetic acid to neutralized chitosan paste samples
placed directly on top of the agar plate where (E) has been loaded with 5 mg/mL vancomycin and (F) has
been loaded with PBS alone.
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Figure 8. Cytocompatibility of normal human dermal fibroblasts treated over 24 and 72 hours with chitosan
paste antibiotic elution samples. Chitosan paste versions were fabricated with an 80:20 ratio of either 0.05
M or 0.15 M acetic acid to neutral chitosan. Cell number results are presented as the average ± the standard
deviation.

Discussion
Systemic antibiotic therapy has shortcomings including insufficient drug
penetration into avascular musculoskeletal wound sites. 20,21 It has also been reported of
local drug delivery devices shifting away from application sites,22,23 reducing antibiotics
delivered to wound tissue flaps and crevices. Using an injectable and adhesive drug
delivery chitosan paste device, with chitosan’s characteristic biocompatible and
biodegradable benefits, as an adjunctive therapy for contaminated musculoskeletal

54

wounds may potentially improve patient outcomes. Our laboratory investigated a
chitosan paste device in an attempt to satisfy this local drug delivery, clinical need.
Few reported studies were found with a design and application related to the
investigated chitosan paste device. In the literature, one research group developed a
chitosan, phospholipid and lauric aldehyde or lauric chloride, injectable blend system
which was analyzed for toxicity and degradation in in vitro and in an intraperitoneally
injected mouse model.24 This system was reportedly biocompatible and biodegradable
over a four week period. Another research group investigated an injectable, microsphere,
crosslinked chitosan-based delivery system for long term drug delivery.25 Their device
was determined to be biocompatible after 20 weeks implantation in an intramuscular
injection, rat model, although it had poor biodegradation properties. Another researcher
developed a thermosensitive and injectable, chitosan and glycerophosphate hydrogel.26
This device resulted in an immediate immune response indicated by inflammatory cell
infiltration and encapsulation of the device after rat model implantation over 21 days.
From the reported studies in this literature review, few in vitro characterization analyses
were performed on material characteristics or device functionality of those injectable
paste local delivery devices.
Our investigated injectable chitosan paste device was created by the hydration of
combined acidic and neutralized chitosan products. Decreased crystallinity and the acidic
presence both indicate higher potential for chitosan paste’s enzymatic and acidic
degradation of the chitosan paste, respectively.27 Acidity levels in any chitosan paste
device will need to be monitored to prevent compatibility issues in planned future in vivo
analyses.28 This investigated chitosan paste product had rapid degradation in vitro, with
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an increased burst elution of loaded antibiotic in comparison to the more long term drug
delivery focus of the other reported devices.29 The chitosan paste device’s elution
samples were observed to be active against S. aureus and cytocompatible after 72 hours
but not at 24 hours. Additionally, our device was quantitatively shown to be injectable in
a clinically relevant range as well as representative adherent against one common
biomaterial. The determined burst antibiotic release and subsequent degradation profiles
of the chitosan paste device may be applicable to initial infection prevention. The paste’s
absorptive and degradation properties may possibly provide further benefits towards
managing wound exudate and reducing wound pain during dressing changes due to its
simple removal, through lavage and irrigation, which may be investigated in future
studies.8,10
Limitations to the experimental approach used in this analysis primarily centered
on the limited number of variables and in vitro test scenarios evaluated. Our evaluation
focused on one chitosan variation in degree of deacetylation and molecular weight, in one
possible ratio combination of fabricated acid to neutralized chitosan products. Only one
common and representative antibiotic, vancomycin, at a single concentration was
investigated for chitosan paste loading against a single, common pathogenic bacterial
strain. Chitosan paste elution and degradation was evaluated at varied and early time
points, since the paste was designed to degrade rapidly. Additionally, controlled paste
adhesion was tested against one possible type of common biomaterial; although in
preliminary screening, chitosan paste testing was analyzed against common metal
implant materials as well as cadaveric, soft muscle tissue with successful, nonquantitative outcomes.
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After initial chitosan paste characterization, one variation in the fabrication, acetic
acid concentration, was analyzed to determine its effects on the paste’s functionality. The
80:20, 0.05 M acetic acid to neutralized chitosan paste version was selected for future
investigation, primarily due to a higher adhesive strength than the other tested variation.
Future work on this paste local delivery method should include an expanded analysis of
those limited test variables in this experimental approach, to ensure the optimization of
the device for its desired adhesive, injectability, drug delivery and degradation
characteristics. Still, in vivo functionality is different from the in vivo environment and
future, pilot studies of the chitosan paste will be necessary to ensure essential
biocompatibility and bacterial reduction in vivo.25
The need for improved injectable and adhesive properties in a degradable and
compatible local drug delivery device in musculoskeletal wound infection prevention was
the major motivation for the development of the chitosan paste device in this study. The
acidic concentration variation in this study was found to have a substantial effect on the
chitosan paste’s characterization and functionality. The in vitro data indicate that the
80:20, 0.05 M acetic acid to neutralized chitosan paste has desired adhesive and
injectable qualities, while also shown to be effective at releasing vancomycin
concentrations over a brief period of time, inhibiting S. aureus growth, with subsequent
device degradation. The preliminary data from theses characterizations suggest the
possibility, with more assessment, of using the chitosan paste device as an adjunctive
therapy for local antibiotic delivery for infection prevention after lifesaving or surgical
treatment to musculoskeletal wounds with discussed additional evaluations..
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Chapter 5
In Vivo Biocompatibility and Infection Prevention Evaluations of an Injectable and
Degradable Chitosan Paste Device

Introduction
A contaminated musculoskeletal wound has the potential to result in infection as
bacteria proliferate among the avascular, non-viable, wound tissues, which is further
complicated by biofilm formation.1,2 Musculoskeletal wound infections impair healing
and may lead to sepsis, amputation, or death, in addition to placing an excessive
economic burden on the patient and society.3-6 Surgical debridement, irrigation, and
systemic antibiotic therapy are standard for musculoskeletal wound management. 4,5,7
Compromised vasculature and decreased blood circulation in musculoskeletal
wounds reduces systemic antibiotic efficacy when achieving bactericidal concentrations
in the local wound environment is vital.8,9 Elevating systemic antibiotic dosages may
result in toxicity prior to reaching local bactericidal concentrations, whereas local
antibiotic delivery systems may provide elevated, local antibiotic levels without causing
toxic effects systemically.2,10-12 Degradable materials such as polycaprolactone,
polyglycolic acid, polylactic acid, poly(lactic-co-glycolic) acid, hyaluronic acid, and their
numerous chemically modified variations provide the benefit of eliminating device
retrieval surgery, however they may be criticized for their inconsistent drug delivery and
potential non-compatible degradation by-products. Local antibiotic delivery systems
fabricated using chitosan are potentially more effective as they may deliver a complete
antibiotic dose without removal as the device degrades into non-toxic byproducts.9,10,13
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Chitosan is a naturally occurring, linear polysaccharide composed of randomly
distributed deacetylated and acetylated units, modified from chitin, commonly sourced
from the exoskeletons of shellfish.14-16 Enzymatic or acidic degradation of chitosan yields
non-toxic saccharide and glucosamine byproducts,17,18 and has a wide range of medical
applications,14 especially as a drug delivery device.13,14,16,19-24 Chitosan has been
investigated for wound site dressing and drug delivery applications with reports of
beneficial hemostasis,25 increased epithelialization rates,26 and antimicrobial effects.27
Additional benefits of injectability and adhesivity may allow for a chitosan device to be
applied to difficult to reach areas within a musculoskeletal wound and remain in the
immediate proximity throughout antibiotic delivery.28
This study evaluated an injectable and degradable chitosan paste in
biocompatibility and infection prevention models. Chitosan paste is fabricated by the
combination of dehydrated acidic and neutralized chitosan powders and hydrated with a
saline or vancomycin solution prior to application (Figure 1). Prior in vitro investigations
established the fabrication procedures for the chitosan paste, developing it as an
injectable and adhesive device that may release an antibiotic over a brief period of time to
inhibit Staphylococcus aureus growth, and subsequently degrade (manuscript submitted
for publication, in press). Our hypothesis was that the chitosan paste would be a
biocompatible, local delivery device that may be loaded with antibiotics for release at a
wound site for the prevention of a local biofilm-forming infection. Our research aim is to
develop and eventually produce a musculoskeletal wound management, adjunctive
therapy, chitosan paste, device that may be loaded with physician selected antibiotics,
injected to adhere to the wound site, delivering the antibiotics locally and preventing
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infection establishment. This preliminary evaluation of the chitosan paste device was
pursued to establish the chitosan paste formulation with in vitro and in vivo
biocompatibility and the ability to prevent a biofilm-forming bacterial infection.

Figure 1. A photograph of the developed chitosan paste being injected from a syringe.

Methods
Fabrication. The chitosan paste was fabricated using Chitopharm S chitosan powder
from Chitinor AS (Haugesund, Norway) with an 82 ± 2 degree of deacetylation (DDA),
251 ± 17 kDa weight-average molecular weight (MW) and 2.013 ± 0.145 polydispersity
index. The chitosan was dissolved at 1 % w/v in 0.05 molar (M), or 0.27 % v/v, acetic
acid in ultrapure water. In an 11×20 cm plastic container, 333 mL of acidic, dissolved
chitosan solution was cast, frozen at -20 °C, and subsequently lyophilized to create a
dehydrated, acidic chitosan product. The dehydrated, acidic chitosan product was
neutralized in 0.6 M sodium hydroxide (NaOH) and washed with copious amounts (> 6
L) of ultrapure water. These neutralized, hydrated sponges were frozen at -20°C and
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lyophilized a second time to create a dehydrated, neutral chitosan product. Dehydrated
acidic and neutral chitosan products were individually, physically ground into a powder
using a blade grinder, with flake sizes at ≤ 0.5 mm diameter, and combined in a ratio of
acidic to neutral chitosan products, represented as a ratio such as 70:30, 60:40, 50:50, or
30:70, to create dehydrated versions of the chitosan paste. For application, dehydrated
chitosan paste was hydrated using a 1× phosphate buffered saline (PBS), in ultrapure
water at 7.5 times the paste’s dehydrated weight.
In Vitro Biocompatibility. The cell viability of normal human dermal fibroblasts
(NHDF) cells, purchased from Lonza (Walkersville, MD), was assessed after treatment
with the chitosan paste variations. Host NHDF cells (passages 4 through 6) were seeded
at 6×104 cells/mL and allowed to proliferate on transparent 12-well polystyrene tissue
culture plates in 2 mL of High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum and penicillin (100 units/mL), streptomycin
(100 mg/mL), amphotericin B (0.25 µg/mL) under standard cell culture conditions (37°C
and 5% CO2 atmosphere). After 24 hours, the cell culture media was refreshed and
approximately 0.5 mL of 70:30, 60:40, and 50:50 chitosan paste versions were
individually loaded into an 8.0 µm pore size membrane, cell culture insert, which was
gently lowered into the cell culture media of one well with a NHDF monolayer (n = 5).
Untreated NHDF cells were used as controls for normalizing cell viability. Cultures were
incubated for 24 and 72 hours and then the chitosan paste containing insert was removed,
and the Promega (Madison, WI) Cell Titer-Glo Luminescent Cell Viability assay was
used to determine cell viability, reported as a percent of the control.

64

Biocompatibility Rat Model. This pilot, implant biocompatibility, animal study protocol
was approved by the University of Memphis Institutional Animal Care and Use
Committee (protocol 0738) for the use of 6 male Sprague-Dawley rats (approximately
390 g). Rats were anesthetized by inhalation of 2% isoflurane in an environmental
chamber and given a sub-cutaneous injection of carprofen in the rat flank. The rat was
prepared for sterile surgery, and anesthesia was maintained using 4 to 5% isoflurane. One
1.5 cm incision was made through the skin on the, back right side of the midline and a
1.25 cm pouch was created in the latissimus dorsi muscle using blunt dissection. In each
muscle pouch, 1 mL of a hydrated chitosan paste test implant, sterilized via low-dose
gamma irradiation (25-40 kGy), was injected from a syringe with a 4 mm diameter, taper
tip cannula. 50:50 and 30:70, acidic to neutral chitosan paste variations were analyzed (n
= 3) and compared to sequentially run, 9.5 mm diameter, disc shaped chitosan sponge,
approximately 5 mm thick. After implantation, the muscle and skin incisions were closed
using a combination of suture and staples. Carprofen was also administered by injection
daily, for two days, post-operatively. The six rats were sacrificed 10 days post-surgery
with the implant and surrounding tissue excised and placed in 10% phosphate buffered
formalin for two days. Tissue sections were bisected across the implant for histological
preparation (paraffin-embedded and hematoxylin and eosin stained). Stained tissue
section slides were visually examined for qualitative analysis using a Nikon inverted
microscope with Eclipse TE300 and BIOQUANT® OSTEO II image analysis software.
Infection Prevention Mouse Model. This established biofilm infection prevention,
animal model protocol was approved by the University of Arkansas for Medical Sciences
Institutional Animal Care and Use Committee (protocol 3461), for the use of 16 NIH
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Swiss mice.29,30 Mice were anesthetized by inhalation of 0.5 to 3% isoflurane and
prepared for aseptic surgery. A 0.3 cm incision was made in the flanks of each mouse
(two sites per mouse), an underneath each incision a subcutaneous pocket was created
using dissection. A 1 cm segment of a 14 gauge Teflon intravenous catheter was
implanted subcutaneously at each surgery site. Adjacent to the catheter, was implanted
either a 0.5 mL, 50:50 chitosan paste sample via syringe with a 4 mm diameter, taper tip
cannula, or a 8 mm diameter, neutralized chitosan sponge control. Each sample, paste or
control sponge, was loaded with either PBS alone or 4 mg/mL vancomycin in PBS. The
paste and control sponge sample variations, and the PBS alone or vancomycin loading
variations, resulted in four test group combinations (n = 8, two implant sites per mouse).
Surgical glue was used to close the incision prior to injecting 1 cc of 10 4 colony forming
units of biofilm forming Staphylococcus aureus UAMS-1 into the lumen of the catheter,
to initiate the infection. At 48 hours post-surgery, the mice were sacrificed and the
catheters removed from each flank and stored in a sterile saline solution. Recovered
catheters were sonicated in PBS to remove adherent bacteria, with aliquots from
appropriately diluted samples plated on tryptic soy agar and incubated at 37 °C overnight
to assess the total number of bacteria recovered from each catheter.
Statistical Analysis. In vitro biocompatibility results are presented as the average ±
standard deviation for the percent cell viability. Statistical analysis on the in vitro
biocompatibility data was performed using two-way analysis of variance, with chitosan
paste formulation and time as factors, followed by Tukey’s post hoc analysis. Recovered
bacterial CFU data, from the infection prevention mouse model, was analyzed using
nonparametric, Kruskal-Wallis one-way analysis of variance to determine if differences
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existed between bacterial CFUs on recovered catheters, followed by Mann-Whitney
analysis. Significance occurred when p ≤ 0.05.

Figure 2. In vitro biocompatibility reported as percent cell viability in comparison to a non-treated control,
for three chitosan paste device variations treatments (via 8 µm pore size, 12 well insert) of normal human
dermal fibroblasts over 24 and 72 hours (n = 5). All acidic chitosan products for the chitosan paste were
fabricated using 0.05 M acetic acid and were combined with neutral chitosan product in 70:30, 60:40, and
50:50 ratios for in vitro biocompatibility. (* represents p < 0.05 versus each other at each time point)

Results
Figure 2 shows the results from the in vitro, biocompatibility evaluation of three
chitosan paste formulations against NHDF cells after 24 and 72 hour treatment times.
After 24 hours of treatment, there was no difference in percent NHDF cell viability
between the chitosan paste variations, also all variations displayed reduced cell viability
compared to the untreated control. However, after 72 hours of treatment with the 70:30
and 60:40 chitosan paste variations, NHDF cells demonstrated a significant decrease (p <
0.01) in cell viability. The cell viability from the 50:50 chitosan paste treatment variation
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increased in comparison to the 24 hour treatment time (0.01 < p < 0.05), similar to the
untreated, control percent cell viability at 100%.
The in vivo biocompatibility was conducted with limited replicates in an
intramuscular, rat back pouch model, which resulted in a mild immune visible response
from the rats which began at 4 days. Visual assessment of all rats implanted with chitosan
paste revealed some stress which included porphyrin secretion and erythema around the
ears, beginning at 4 days post-operation until sacrifice at 10 days. Rats with the 30:70
chitosan paste version had less secretion and erythema than in those implanted with the
50:50 chitosan paste version. None of the control chitosan sponge implanted animals
exhibited the secretion or erythema. Histological analysis of recovered implant tissue
sections, did reveal an elevated inflammatory response as indicated by dark purple,
immune cell migration to the defect area surrounding the reddish/orange, chitosan paste
near the sponge/tissue interface (Figures 3 and 4). Inflammatory response and fibrous
encapsulation that formed around the implant was similar between the two chitosan paste
versions. There were more fibroblast and immune cell infiltration into the internal spaces
between the fiber-like layers in the 30:70 chitosan paste version (Figure 3B) in
comparison to the 50:50 chitosan paste version (Figure 3A) which appeared to have
congealed into nearly a solid mass of chitosan. The 30:70 chitosan paste version (Figure
3B) appeared more similar to control chitosan sponge implants with respect to the fiberlike morphology (Figure 4).
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A

B

Figure 3. A light microscope image of a representative histological tissue section taken 10 days postsurgery from a rat intramuscular, back pouch rat model implanted with a 1 mL sample of 50:50, acidic to
neutralized chitosan paste device (A) and a 1 mL sample of 30:70, acidic to neutralized chitosan paste
device (B), hematoxylin and eosin stain (10x). * indicates chitosan
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Figure 4. Light microscope image of a representative histological tissue section taken 10 days post-surgery
from a rat intramuscular, back pouch rat model implanted with a double-lyophilized, neutral chitosan
sponge device, hematoxylin and eosin stain (10x). * indicates chitosan

In vivo mouse, biofilm forming Staphylococcus aureus, infected catheter model
are presented as the average CFU per catheter (Figure 5). Statistical analysis revealed a
difference in CFU counts between each group (p < 0.015) except for when the
vancomycin loaded chitosan sponge group is compared to the vancomycin loaded
chitosan paste group. Control, PBS loaded implants demonstrated colony forming unit
levels in recovered catheters which were significantly reduced, by 3 to 4 orders of
magnitude, in the vancomycin loaded implant groups (p < 0.01).
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Figure 5. Average number of Staphylococcus aureus colony forming units per catheter, retrieved from each
chitosan paste and chitosan sponge control group after a 48 hour treatment (n = 8). Groups analyzed for
biofilm prevention included neutralized chitosan sponges and 50:50, acid to neutralized chitosan paste
variation samples each loaded with either PBS alone or 4 mg/mL vancomycin (four groups total, n = 8 per
group). All groups are significantly different except for the comparison of the two vancomycin loaded
groups (p < 0.015).

Discussion
Musculoskeletal infections and biofilm formation is a serious problem and burden
to the patient and society.1,2,6 The clinical need due to reduced efficacy of systemically
delivered antibiotics to penetrate and diffuse through the wound to a contaminating
source,8-12 has resulted in the investigation of an injectable and adhesive chitosan paste
for local antibiotic delivery through topical or implantable applications. Our hypothesis
was that the chitosan paste, fabricated as a combination of dehydrated 0.05 M acetic
acidic and neutralized chitosan powders, with subsequent hydration for application,
would result in a compatible local antibiotic delivery device for infection prevention and
related biofilm.
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After establishing in vitro biocompatibility of the chitosan paste, resulting
formulations were evaluated in intramuscular, rat, back pouch biocompatibility and
subcutaneous, mouse, catheter biofilm infection prevention models. The in vitro and in
vivo evaluations produced different biocompatibility results. While the 50:50 chitosan
paste version was cytocompatible after three days in vitro, neither the 50:50 or 30:70
chitosan paste variations were implanted in the in vivo biocompatibility model without
eliciting a slight immune response. Still, the injectable and antibiotic loaded, 50:50
chitosan paste versions produced no evident immune responses after the 48 hour
treatment in the mouse, subcutaneous, catheter infection prevention model.
Comparing the chitosan paste device to the literature, there are some similarities
to other published investigations into implantable chitosan devices. 31-33
Histomorphometric evaluation of the 50:50 chitosan paste formulation displayed a
chitosan morphology that was more similar to evaluations performed on chitosan
composite scaffolds by Dr. Reves,33 where BMP-2 loaded porous, composite chitosannano-hydroxyapatite scaffolds were prepared by the acetic acid buffer fusion of
degradable chitosan-nano-hydroxyapatite beads. Intended for osteogenic applications, the
scaffolds appeared in histological imaging from a rat muscle-pouch model, as solid,
spherical, residual chitosan masses, partially integrated by new bone tissue at the porous
interfaces. Alternatively, the 30:70 chitosan paste formulation was more similar in
comparison to the chitosan sponge control. The chitosan sponge, adjunctive, drug
delivery wound dressing was also evaluated in vivo by Noel et al.32 In an intramuscular,
rat, back pouch model, the chitosan sponge device, fabricated as a neutral, lyophilized,
construct of interconnected thin chitosan sheets, appeared to have significant fibroblast or
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granulation tissue integration among the, interconnected fiber-like layers of the chitosan
sponge. In another investigation by Son et. al., a thermosensitive, injectable, chitosan
based hydrogel was developed for drug delivery applications.31 The chitosan and
glycerophosphate combination, pH dependent gel was evaluated for histomorphometry
after implantation in rats and was found to cause fibrous encapsulation and cellular
immune response as soon as three days after implantation similar to what was seen in the
chitosan paste’s evaluation after 10 days implantation.
By reviewing and comparing these studies in the literature,34-36 the incorporation
of acidic chitosan paste into the chitosan device may contribute to the reduced in vivo
biocompatibility of the chitosan paste formulation. The acid concentration within the
implant paste was well below the reported median lethal dose for injection. The
combination of paste adhesion and degradation, low acidic concentration in the chitosan
paste may result in reduced biocompatibility.16,37 An additional, possible contributing
factor to the chitosan paste’s reduced biocompatibility, may be the high initial chitosan
molecular weight, resulting in an influx of high levels of dissolved chitosan polymer,
which the local tissue may not readily eliminate, transport, degrade from the local
implant site.37
This study was limited by small animal rat and mice models, and these small
animal models are not the most clinically relevant models for comparison to the large,
open, complex, biofilm infected musculoskeletal extremity wounds found in complex
trauma. These results partially confirmed the stated hypothesis, that the application of the
adjunctive, local drug delivery, chitosan paste device can prevent infection establishment.
Additional work is needed to improve biocompatibility, and to determine the differences
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between in vitro cytocompatibility and in vivo biocompatibility in the paste. With more
research the injectable and adhesive chitosan paste formulations or alternative
biomaterials may better meet the clinical need for a degradable, local drug delivery
device whose adjunctive application to musculoskeletal wounds may prevent biofilm and
related infections.
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Chapter 6
Conclusions

To be applicable for musculoskeletal wound infection prevention, the chitosan
paste device was required to be injectable, adhesive, biodegradable, biocompatible and
able to absorb and release antibiotics. For this reason the chitosan paste was characterized
and functionally tested in vitro and in vivo.
Table 1 gives a summary of the key abilities analyzed in vitro and in vivo for the
chitosan sponge and chitosan paste devices analyzed. While not a direct assessment of the
chitosan paste, Chapter 2 partially showed chitosan’s potential as a related, implantable
and non-toxic, acid modified sponge device. The results indicated the importance of
balancing the numerous characteristic variables in chitosan devices for its optimization to
a specific application. The chitosan sponge (Chapter 2) and paste (Chapter 3) device
evaluations cannot be directly compared due to variations in the testing methods.
However, generally, in vitro conclusions found in chapters 1 and 2 were similar for
biocompatibility and drug delivery capabilities (see also, Appendix 1 and 2),39,65 but the
chitosan paste (Chapter 3) showed an improved biodegradability as compared to the
sponge. In vivo, rat muscle-pouch implant degradation for the chitosan sponge (Chapter
2) and chitosan paste (Chapter 4) was reduced in both devices as compared to their in
vitro analyses. Both the chitosan sponge65 and chitosan paste (Chapter 4) exhibited trends
toward improved infection prevention in the in vivo, infected catheter with a biofilm
organism, mouse model. Additionally, although beneficial in certain situations (Appendix
3), the chitosan paste presents a definite improvement over chitosan films and
coatings,50,65,66 as well as the chitosan sponge,39,55,65,67 due to the added injectability and
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adhesivity abilities, suggesting the chitosan paste as a more effective musculoskeletal
wound infection prevention device.

Table 1. A general summary of the results found in the investigation of the chitosan
sponge and paste devices where “×” indicates overall supporting evidence for the
listed device ability. The (Chapter #) indicates the chapter within this body of work
where the specific ability of the device is analyzed. * indicates that the analysis of this
device ability may be found in Appendix 3. ** indicates that the analysis of this device
ability may be found in Chapter 4.
Description of
the Device’s
Ability

In vitro
Chitosan
Sponge
(Chapter 2)

In vivo
Chitosan
Sponge
(Chapter 2)

In vitro
Chitosan
Paste
(Chapter 3)

In vivo
Chitosan
Paste
(Chapter 4)

Acid Modified
Device

×

×

×
×
×

×
×
×*

×

×
×
×
×
×
×

Injectable
Adhesive
Non-toxic
Biodegradable
Antibiotic
Delivery

×**

×

Chapter 3 described an in vitro evaluation of the chitosan paste specifically
analyzing one key variable in the chitosan paste fabrication, the acid concentration. This
analysis resulted in a better understanding of this individual variable within the context of
the chitosan paste device and indicated positive results for biodegradability and
biocompatibility. Due to successes in vitro (Chapter 3), in vivo assessment of the chitosan
paste was performed (Chapter 4) with results that indicated reduced biocompatibility but
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promising infection prevention functionality. These results indicate the need for additional
evaluations of redesigned chitosan paste versions as recommended in Chapter 6.
In summary, the results are understood to be a partial confirmation of the stated
hypothesis, that the application of the adjunctive, local drug delivery, chitosan paste
device to an open musculoskeletal wound will prevent infection establishment. While
additional work is needed to overcome reduced biocompatibility of the device, the results
demonstrated the potential for the injectable and adhesive, chitosan paste device for
infection prevention applications in musculoskeletal wounds. With applied
enhancements, this device should meet the clinical need for a degradable, local drug
delivery device whose effective, adjunctive application as to musculoskeletal wound
infection prevention and low fabrication costs should aid in reducing both patient and
socioeconomic burden.
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Chapter 7
Recommendations for Future Work

Additional target evaluations should be performed to develop a more thorough
understanding of the chitosan paste device, and optimize its fabrication for application as
an injectable and adhesive, local antibiotic delivery device for musculoskeletal wound
infection prevention. With the acid concentration and hydration rate used for the paste as
described in chapter 3 of this dissertation, modifying the originally used chitosan powder
material to a lower molecular weight, degree of deacetylation and crystallinity may
provide further improvements to the device’s biodegradability and biocompatibility.
These modifications to the chitosan product would necessitate a reevaluation of the acidic
to neutral chitosan paste ratio, with the possibility of producing even more effective
adhesivity and injectability properties.
Deviations from the chitosan paste versions evaluated in this dissertation should
be evaluated using the in vitro methods as described in Chapter 3 to establish the
version’s injectability and adhesivity, as well as antibiotic delivery and eluate activity
properties, with special attention to biocompatibility evaluations. These assessments
should also be expanded to evaluate the delivery of antibiotics other than vancomycin,
and tested against other bacteria in addition to Staphylococcus aureus.
It is recommended that the resulting, optimized chitosan paste variation be applied
in a pilot (limited replicates), in vivo, large animal model. A large animal, subdermal or
intramuscular model would allow for the chitosan paste’s biodegradability and
biocompatibility to be assessed in a more clinically relevant environment. The more
efficient chitosan paste version should be reevaluated in the small animal, mouse,
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catheter biofilm prevention model to establish antibiotic dosing while limiting costs and
time prior to preforming large animal, extremity musculoskeletal infection prevention
models with chitosan paste treatment. Further expansion of in vivo testing or
reassessment of the device fabrication with additional in vitro modification would be
dependent upon the chitosan paste’s success in these animal models. Success in these
pilot animal models would suggest a biocompatible, biodegradable chitosan paste device
for application in musculoskeletal infection prevention.
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Appendix A
Chitosan Sponges for Local Synergistic Infection Therapy: A Pilot Study

Introduction
Bacterial resistance against current, first-line antibiotics continues to be a growing
problem throughout the world.8, 27 The shortage of novel antibiotics or antibiotic classes
in development and the overuse of available antibiotics have made alternative therapies
for resistant bacterial infections necessary. Proper antibiotic use is and will continue to be
a critical factor in infection control.8 Limitations of standard therapeutic options have led
to increases in cost, toxicity, treatment time, and intensive care admissions. In the United
States alone, the cost of treating antibiotic-resistant infections reportedly ranges from
USD 18,588 to USD 29,069 per patient with extended hospital stays ranging from 6.4 to
12.7 days and with an estimated mortality rate of 6%.10, 33 It is estimated that methicillinresistant Staphylococcus aureus (MRSA) kills 19,000 people in the United States each
year.22 In the medical community, hospital-acquired infections occur primarily at surgical
sites with an increased risk when using orthopaedic implants or other surgical devices.12
Growth of antibiotic resistance threatens to negate sophisticated treatments like hip
replacements, organ transplants, care of preterm infants in addition to routine surgical
procedures.8, 9
New approaches are needed to address the global threat of antibiotic resistance.7, 8
One long-term goal to reduce antibiotic resistance is the worldwide, controlled use of
antibiotics.7 Additionally, alternative therapeutic approaches are being investigated for
improving dose-response of commonly used antibiotics as well as the use of nonantibiotic
therapies such as antiseptic.26 One of these alternative approaches is the use of multidrug
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treatment strategies that exploit pharmacodynamic synergy between antiseptics and
antibiotics to combat specific bacterial infections.17 Pharmacodynamic synergism occurs
when the antiseptic and antibiotic combination has a greater effect on the microbial target
than the sum of the drugs’ effects individually.3 However, just as important as selecting
appropriate therapeutics is their efficient delivery to the infection site.24 The local
delivery of the selected antiseptics and antibiotics to the infection site reduces the effects
of metabolism and degradation, thus providing high local drug concentrations while
minimizing systemic toxicity.29 We explored the use of chlorhexidine digluconate (CHX)
as a model antiseptic that is commonly used in hospitals for topical and oral
decolonization treatments and is bactericidal against a broad spectrum of bacteria.6, 23, 26,
32

We asked the following questions in this pilot study: Do any of the combinations
of the antiseptic CHX with daptomycin (DAP), vancomycin (VAN), or amikacin (AMK)
result in synergism against S aureus? Does the synergistic combination reduce the
viability of cells? Can this synergistic combination be delivered at bacteriostatic
concentrations using a biocompatible and biodegradable chitosan sponge?
Materials and Methods
To answer these preliminary questions (Figure 1), first we tested the ability of the
combinations of CHX with AMK, DAP, or VAN to synergistically inhibit growth of S
aureus (n = 1). The combination that produced synergism was then analyzed for its
effects on NIH/3T3 fibroblast cell viability compared with controls grown on tissue
culture plastic (n = 3). Finally, we evaluated the release profile of the drugs individually
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1
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Methods:

Groups:

Pharmacodynamic
Evaluation (n=1,
147 Total Samples)

Chlorhexidine
Digluconate and
Daptomycin
Chlorhexidine
Digluconate and
Amikacin
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Digluconate and
Vancomycin

Tissue Culture
Plastic Control

2

nd

Cell Viability
Assay (n=3,
108 Total Samples)

Chlorhexidine
Digluconate
Alone

rd

In Vitro Elution
Testing (n=5,
120 Total Samples)

Vancomycin
Alone

Drug Activity
Assay (n=5,
100 Total Samples)

Chlorhexidine
Digluconate and
Vancomycin

3

4

th

Positive Control

Negative Control

Figure 1A. flowchart summarizes the study design.

and in combination using a previously investigated chitosan sponge device (n = 5) and
also tested the eluate samples for drug activity against S aureus (n = 5).
The underlying method used in synergism analysis was turbidity testing. In the
turbidity assay, a solution containing a 1:10 dilution of the samples in 0.2 M calcium-
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supplemented Mueller Hinton II broth (BD, Franklin Lakes, NJ, USA) was inoculated
with S aureus (Cowan I) and incubated overnight at 37°C. We quantified growth by
measuring the absorbance at 530 nm.29 Lack of growth was indicated by absorbance
values equivalent to negative controls. The minimum inhibitory concentration (MIC) is
the lowest concentration that completely inhibits growth. We determined the MIC for
each individual drug, chlorhexidine digluconate (MP Biomedical, Salon, OH, USA),
amikacin (MP Biomedical), daptomycin (Cubist Pharmaceuticals, Lexington, MA, USA),
and vancomycin (MP Biomedical), by turbidity analysis. The pharmacodynamic
interaction among each of the drug combinations, CHX + AMK (n = 1), CHX + DAP (n
= 1), and CHX + VAN (n = 1), was determined by combining a range of concentrations
of the drugs in a checkerboard method and testing a matrix of each combination at
multiple concentrations (7 x 7 matrix per number) for their effect on the growth of S
aureus.25 We then calculated the fractional inhibitory concentration (FIC) for each drug
by dividing its MIC when used in combination by its MIC when used alone.3 The FIC
index is the sum of the two drugs’ FICs given by the equation: FIC index = FIC A + FICB
= (MIC of drug A in combination/MIC of drug A alone) + (MIC of drug B in
combination/MIC of drug B alone). When the FIC index is less than 0.5, then the
combination is synergistic; if the index is greater than 0.5 or less than 2, then the
combination is additive; if the index is greater than 2 or less than 4, then the combination
is indifferent; and if the index is greater than 4, then the combination is antagonistic
(Table 1).3 We determined the FIC index for combinations of CHX + AMK, CHX +
DAP, and CHX + VAN.
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Table 1. Minimum Inhibitory Concentration (MIC), Fractional
Inhibitory Concentration (FIC) index and the resulting effect for
various antimicrobials against S. aureus.
Antimicrobial

MIC (µg/mL)

FICI

Effect

AMK

0.5

-

-

DAP

0.5

-

-

VAN

0.5

-

-

CHX

0.5

-

-

CHX + AMK

-

0.750

Additivity

CHX + DAP

-

1.500

Additivity

CHX + VAN

-

0.375

Synergism

FIC index < 0.5 indicates synergy, 0.5 ≤ FIC index < 2.0
indicates additivity, 2.0 ≤ FIC index < 4.0 indicates
indifference and FIC index ≥ 4.0 indicates antagonism (n = 1).

We only evaluated the antiseptic and antibiotic that provided synergism for
effects on host cell viability. We evaluated the effects of synergistic combinations of
CHX + VAN (n = 3), CHX alone (n = 3), and VAN alone (n = 3) on host cell viability
using NIH/3T3, mouse embryonic fibroblast cells ATCC #CRL-1658 (Manassas, VA,
USA). The host NIH/3T3 fibroblasts grown on tissue culture plastic without treatment
were used for a control. Cells were seeded at 2 x 104 cells/cm 2 in 108 wells of 96-well
plates in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum and allowed to proliferate overnight in standard culture conditions (37°C, 5%
CO2). We used twofold serial dilutions in media to create a range of nine treatment
standards from 1000 µg/mL to 0.49 µg/mL for each drug group (four total groups with n
= 3 and nine treatment dilutions). The group with the CHX + VAN combination
contained each at the concentrations indicated. Cells were treated for 24 hours with the
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appropriate antiseptic and/or antibiotic of drug group standards. The CellTiter-Glo
Luminescent Cell Viability assay (Promega, Madison, WI, USA) was then used to
determine the number of viable, metabolically active NIH/3T3 fibroblast cells after
treatment with standard concentrations. This assay quantifies ATP, which is correlated to
the number of metabolically active and viable cells, based on a luminescent signal
obtained using a 96-well plate reader at 590 nm (FLx800; Bio-Tek, Ontario, Canada).
We then used the same three antiseptic and antibiotic groups for in vitro elution
testing to determine release profiles. Chitosan sponges for each group were manufactured
using previously described methods29 with five replicates used as the local delivery
device for each group of antibiotic combinations. Briefly, the chitosan sponges were
manufactured with 1% (w/v) of 71% deacetylated chitosan Primex (Siglufjordur, Iceland)
dissolved in a 1% (v/v) blended lactic/acetic acid solvent (75:25, respectively). The
solution was filtered through a 180-µm nylon mesh (Gilson, Lewis Center, OH, USA),
frozen at ‒80 °C, and subsequently lyophilized (FreeZone 2.5; Labconco, Kansas City,
MO, USA). The dehydrated sponge was then neutralized in 1 M (molar) NaOH (Fisher
Scientific, Fair Lawn, NJ, USA), washed with distilled/deionized water, frozen at ‒80 °C,
and lyophilized (Figure 2). We initiated elution testing by hydrating these twice
lyophilized sponges, normalized by weight (n = 5), for 1 minute in 50 mL of drug
solution comprised of 5 mg/mL VAN (n = 5), CHX (n = 5), or CHX + VAN (n = 5) with
each drug in the combination at 5 mg/mL. The drug-loaded sponges were then transferred
into a 125-mL Nalgene container with 20 mL of phosphate buffered saline (PBS) and
then incubated at 37 °C. Solution samples were taken at 1, 2, 5, 10, 14, and 21 days with
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complete PBS solution replacement at each time point. We immediately froze samples
after acquisition.

Figure 2A-B. (A) The dehydrated chitosan sponge before testing before testing and a (B) scanning electron
micrograph at x30 of the same sponge show the high surface area, laminar morphology of the sponge

We analyzed elution samples for drug concentration using high-performance
liquid chromatography. The chemical separation was carried out using a reversed-phase
C18 column (Varian) with a mobile phase consisting of 30% acetonitrile and 70% buffer
with all chemicals purchased from Fisher Scientific. The buffered solution was 0.1 M
phosphate buffer consisting of 0.08 M disodium phosphate and 0.013 M monosodium
phosphate adjusted to pH 3 using phosphoric acid. Using a flow rate of 1.4 mL/min and
UV detection at 250 nm, VAN had a 1.5-minute retention time, whereas CHX’s was 5
minutes. We also evaluated elution samples in a 10:1 dilution for activity to determine
whether the elution process substantially altered or prevented the drug’s bacteriostatic
ability. This evaluation used turbidity testing as described earlier with results indicated as
either bacterial growth or inhibition.
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We determined differences in host cell viability and drug release studies by using
two-way analysis of variance with Tukey’s post hoc analysis follow up. Statistical
analysis was performed using SigmaPLOT Version 12 (San Jose, CA, USA).
Results
The MIC was 0.5 µg/mL for AMK, DAP, VAN, and CHX when tested against S
aureus (Table 1). The FIC index was 0.75 for the combination of CHX and AMK
indicating they were pharmacodynamically additive but not synergistic. The combination
of CHX and DAP gave an FIC index of 1.5, also indicating additivity. However, the
combination of CHX and VAN exhibited synergism as indicated by an FIC index of
0.375. This synergistic combination was the only one used in subsequent testing along
with CHX and VAN individually.
CHX reduced the percent fibroblast cell viability in comparison to the control
group at concentrations ≥ 3.91 µg/mL, whereas the CHX + VAN combination decreased
proliferation at ≥ 7.81 µg/mL (Figure 3). In contrast, VAN-treated fibroblasts remained
viable across the entire range of concentrations tested.
Both the antiseptic and antibiotic were released in an initial bolus elution. With
the exception of VAN on Day 5, there were no differences between a singular drug’s
release profiles when it was released individually or in combination with another drug
(Figure 4). At the Day 1 and 2 time points, VAN alone and in combination was released
at higher concentrations than either CHX released alone or in combination. At the Day 5
time point, only individually released VAN was substantially higher than the other eluate
concentrations and after the Day 5 time point, there were no major differences among any
of the eluate data points. All test groups containing CHX, VAN, or CHX +VAN were
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inhibitory against S aureus, except for VAN released alone at later time points of 5, 10,
14, and 21 days (Table 2).

Figure 3. CHX, VAN, and CHX + VAN cell viability. Viability is reported as the percent of viable cells in
comparison to cell proliferation controls (n = 3).

Figure 4. CHX, VAN, and CHX + VAN release from chitosan sponges. The CHX + VAN release profile
is broken down to show each drug individually. Concentrations are given in micrograms per milliliter ±
SD on a logarithmic scale (n = 5).
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Table 2. The average activity for eluate samples against S. aureus.
Antimicrobial

Time (days)
1

2

5

10

14

21

VAN

‒

‒

+

+

+

+

CHX

‒

‒

‒

‒

‒

‒

CHX + VAN

‒

‒

‒

‒

‒

‒

"-" indicates no S. aureus growth and "+" indicates S. aureus
growth (n = 5).

Discussion
Increases in bacterial antibiotic resistance, both from the overuse and misuse of
antibiotics, along with fewer new antibiotics, have all affected clinical treatment
approaches.7, 17 The severe impact of antibiotic-resistant infections has led to the search
for new and more efficient therapeutic applications.19, 34, 36, 38 Some of these methods
include using pharmacodynamic synergism between two drugs against bacterial species.
Additionally, a localized delivery device is able to provide high concentrations of drugs
at the specific site of infection while limiting systemic concentrations and associated
complications.28 Combining synergistic dual-drug therapy with local drug delivery may
provide more efficient use of antibiotics and antiseptics, thus decreasing the total
concentration necessary for infection treatments. We therefore asked the following
questions: Do any of the combinations of the antiseptic CHX with DAP, VAN, or AMK
result in synergism against S aureus? Does the synergistic combination reduce the
viability of cells? Can this synergistic combination be delivered at bacteriostatic
concentrations using a biocompatible and biodegradable chitosan sponge?
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Limitations on this pilot study include, first, that we studied only three antibiotics
and one antiseptic was evaluated against one specific strain of bacteria in this preliminary
screening approach. These drugs, all active against MRSA, were evaluated first against S
aureus because it is one of the major concerns in orthopaedic infections.21 The clinical
application for the investigated therapy would be greatly enhanced by increasing the
selection of synergistic drug combinations and by their evaluation against a large array of
bacterial species. Additionally, knowing the therapeutics’ effects against human cell lines
could prevent the possibility of increased toxicity of synergistic drug combinations.
Second, the translation of in vitro evaluation to in vivo evaluation cannot be generalized
and, therefore, it is not known yet whether our in vitro results can be generalized to in
vivo application. Third, although our data suggest the CHX + VAN combination does not
affect the elution of either drug out of the chitosan sponge in contrast to other dual-drug
delivery therapies,4 we have not shown that the antiseptic and antibiotic will diffuse into
an in vivo wound environment similarly. Fourth, the complex biological conditions found
in the wound were not modeled in this investigation. Like in previous studies, this model
is a simple screening approach to predict which therapeutic combinations should be
evaluated in in vivo models1, 15, 20 Additionally, there are more detailed studies that could
be performed such as a disc diffusion method for evaluating nondiluted eluate activity
against bacteria as well as an enhanced elution study with more frequent sampling time
points.
Using the standard calculation of FIC index for determining pharmacodynamic
effects, we identified synergism in the CHX + VAN combination. Synergism was
identified through techniques similar to other investigations using alternative synergistic,
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dual-drug therapies against bacteria.2 The combination of CHX with protamine sulfate
has in vitro synergism for combinatorial therapy against Escherichia coli.11 CHX has
synergism with hydrogen peroxide against Streptococcus sobrinus, Streptococcus
faecalis, and Staphylococcus aureus.35 VAN has a low degree of synergism with the
antibacterial nisin against some S aureus strains.13 Also, VAN has synergism with
sulfamethoxazole/trimethoprim and rifampin against some Staphylococcus strains;
however, when combined with imipenem and other drugs, VAN has synergistic effects
against a broader range of methicillinresistant, coagulase-negative, and biofilm forms of
Staphylococcus.30, 34 The synergism between CHX and VAN, like with the other
examples mentioned, may ultimately allow for the reduced amount of total drug dosage
clinically as well as greater antibiotic efficacy, coverage of multiple strains, and
decreased incidence of resistance.
First used in the 1950s, CHX’s toxicity was quickly noted but was minimal when
used in topical and oral applications.16 CHX has been successfully used as a prophylactic
treatment for surgical site infection prevention.6, 31 When used in local drug delivery,
although systemic concentrations remain low, there may be a transiently high
concentration of local drug, which could cause a delay in the wound healing process. For
this reason, the release profile of CHX needs to be well characterized to minimize
possible interference with inflammatory and proliferative processes in musculoskeletal
wound healing.14 Reassessing the loading profile and modifying sponge parameters or the
delivery device to minimize negative impacts on wound and bone healing processes can
be pursued with more comprehensive in vivo work. In our study, CHX also exhibited
toxicity toward NIH/3T3 cells at concentrations of average 3.91 and 7.81 µg/mL in
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comparison to the 0.5 µg/mL level needed to inhibit bacterial growth. Our CHX and
VAN loaded delivery device delivered concentrations that were above this toxic level at
time points 1, 2, and 5 days but after this dropped below the toxic threshold. The possible
advantages of preventing the growth of S aureus and the development of antibioticresistant strains may justify this potential delay in healing. Surprisingly, the VAN + CHX
combination slightly reduced the toxic concentration’s effects. It is generally accepted
that the local delivery of drugs provides results typically in a relatively low systemic drug
concentration.28 An in vivo study using chitosan sponges to locally deliver VAN loaded at
5 mg/mL to a S aureus-infected goat extremity musculoskeletal wound substantially
decreased bacterial contamination with near negligible serum VAN concentrations.37
In contrast to other local drug delivery systems, the highly open and laminar
structure of the chitosan sponge (Figure 2) allows for the initial bolus release of the CHX
+ VAN combination with a release profile similar to their individual elution.29 The bolus
release is contrasted with other local drug delivery systems such as bone cement, which
exhibits slow and incomplete release of individually loaded antibiotics and unequal
release profiles in dual drug- loaded constructs.4, 18 Bone cement’s unfavorable qualities
reportedly result from its low porosity5, 18; however, the high porosity and surface area of
a chitosan sponge does not inhibit the release of either CHX or VAN over the other drug.
This property is expected to be beneficial for diffusion of dual-drug therapy in which
both drugs will be released at active concentrations simultaneously, enabling their
synergistic bacteriostatic activity. Furthermore, bolus release may be more appropriate
than slow, extended release for delivery of CHX in that it minimizes tissue exposure to
toxic levels of this antiseptic.
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The major motivation for this study was the need for efficient use of currently
available antiseptics and antibiotics to prevent orthopaedic surgical site infections by
exploiting synergism between an antiseptic and antibiotic. We further identified and
explored methods to deliver drug combinations locally at high concentrations without
substantially altering the drugs’ release profile. Our data suggest the synergistic
combination of CHX + VAN can be delivered at concentrations that are inhibitory to an S
aureus strain. Although CHX has poor biocompatibility at high concentrations, local drug
delivery of CHX is expected to release an initial bolus of CHX while keeping systemic
concentrations at nontoxic levels. Over the course of 5 days, the local CHX release is
expected to drop to biocompatible levels yet still be inhibitory to bacteria. Future research
should include evaluation of expanded combinations of antiseptics and antibiotics in vitro
and in vivo. Specifically, in vivo validation of this treatment method should be performed
in comparison to standard systemic and local infection treatments in an infected animal
model.5, 37 The data also suggest the addition of local drug delivery to the efficient use of
antiseptics and antibiotics agents through their synergic effects may provide alternative
therapies for infection treatment in a world where the future of antibiotics is uncertain as
a result of decreased novel antibiotics and increased antibiotic resistance.
References
1.

Adams K, Couch L, Cierny G, Calhoun J, Mader JT. In vitro and in vivo
evaluation of antibiotic diffusion from antibiotic impregnated
polymethylmethacrylate beads. Clin Orthop Relat Res. 1992;278:244–252.

2.

Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M, Rafailovich M. Coping
with antibiotic resistance: combining nanoparticles with antibiotics and other
antimicrobial agents. Expert Rev Anti Infect Ther. 2011;9:1035–1052.

3.

American Society for Microbiology. Instructions to authors. Antimicrob Agents
Chemother. 2004;48:i–xx.
101

4.

Anagnostakos K, Kelm J. Enhancement of antibiotic elution from acrylic bone
cement. J Biomed Mater Res B Appl Biomater. 2009;90:467–475.

5.

Beenken KE, Bradney L, Bellamy W, Skinner RA, McLaren SG, Gruenwald MJ,
Spencer HJ, Smith JK, Haggard WO, Smeltzer MS. Use of xylitol to enhance the
therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in
treatment of chronic osteomyelitis. Antimicrob Agents Chemother. 2012;56:
5839–5844.

6.

Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly
effective regimen for decolonization of methicillin-resistant Staphylococcus
aureus carriers. Infect Control Hosp Epidemiol. 2008;29:510–516.

7.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA,
Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya
O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A,
Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P,
Zgurskaya HI. Tackling antibiotic resistance. Nat Rev Microbiol. 2011;9:894–
896.

8.

Chan M. Antimicrobial resistance in the European Union and the world.
Conference on Combating Antimicrobial Resistance. Copenhagen, Denmark:
World Health Organization; 2012.

9.

Darouiche RO. Antimicrobial approaches for preventing infections associated
with surgical implants. Clin Infect Dis. 2003;36: 1284–1289.

10.

Darouiche RO. Treatment of infections associated with surgical implants. N Engl
J Med. 2004;350:1422–1429.

11.

Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Efficacy of
combination of chlorhexidine and protamine sulphate against device-associated
pathogens. J Antimicrob Chemother. 2008;61:651–657.

12.

Diefenbeck M, Muckley T, Hofmann GO. Prophylaxis and treatment of implantrelated infections by local application of antibiotics. Injury. 2006;37(Suppl
2):S95–104.

13.

Dosler S, Gerceker AA. In vitro activities of nisin alone or in combination with
vancomycin and ciprofloxacin against methicillin- resistant and methicillinsusceptible Staphylococcus aureus strains. Chemotherapy. 2011;57:511–516.

14.

Drosou A, Falabella A, Kirsner RS. Antiseptics on wounds: an area of
controversy. Wounds. 2003;15:149–166.
102

15.

Farhana SA, Shantakumar SM, Narasu L. Sustained release of diltiazem
hydrochloride from chitosan micro-capsules. Curr Drug Deliv. 2009;6:238–248.

16.

Foulkes DM. Some toxicological observations on chlorhexidine. J Periodontal
Res Suppl. 1973;12:55–60.

17.

Guillemot D. Antibiotic use in humans and bacterial resistance. Curr Opin
Microbiol. 1999;2:494–498.

18.

Hiraishi N, Yiu CK, King NM, Tay FR. Chlorhexidine release and antibacterial
properties of chlorhexidine-incorporated polymethyl methacrylate-based resin
cement. J Biomed Mater Res B Appl Biomater. 2010;94:134–140.

19.

Itokazu M, Matsunaga T, Kumazawa S, Yang W. A novel drug delivery system
for osteomyelitis using porous hydroxyapatite blocks loaded by centrifugation. J
Appl Biomater. 1995;6: 167–169.

20.

Jia WT, Luo SH, Zhang CQ, Wang JQ. In vitro and in vivo efficacies of
teicoplanin-loaded calcium sulfate for treatment of chronic methicillin-resistant
Staphylococcus aureus osteomyelitis. Antimicrob Agents Chemother.
2010;54:170–176.

21.

Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA.
Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site
infections in orthopedic surgery. Infect Control Hosp Epidemiol. 2000;21:319–
323.

22.

Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH,
Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal
LK, Carey RB, Fridkin SK. Invasive methicillin-resistant Staphylococcus aureus
infections in the United States. JAMA. 2007;298:1763–1771.

23.

Kuyyakanond T, Quesnel LB. The mechanism of action of chlorhexidine. FEMS
Microbiol Lett. 1992;79:211–215.

24.

Levy SB. Antibiotic resistance—the problem intensifies. Adv Drug Deliv Rev.
2005;57:1446–1450.

25.

Lorian V, ed Antibiotics in Laboratory Medicine. 5th ed. Philadelphia, PA, USA:
Lippincott Williams & Wilkins; 2005.

26.

Muller G, Kramer A. Biocompatibility index of antiseptic agents by parallel
assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob
Chemother. 2008;61:1281–1287.
103

27.

Nathan C. Antibiotics at the crossroads. Nature. 2004;431:899–902.

28.

Nelson CL. The current status of material used for depot delivery of drugs. Clin
Orthop Relat Res. 2004;427:72–78.

29.

Noel SP, Courtney HS, Bumgardner JD, Haggard WO. Chitosan sponges to
locally deliver amikacin and vancomycin: a pilot in vitro evaluation. Clin Orthop
Relat Res. 2010;468:2074–2080.

30.

Pammi M, Liang R, Hicks JM, Barrish J, Versalovic J. Farnesol decreases
biofilms of Staphylococcus epidermidis and exhibits synergy with nafcillin and
vancomycin. Pediatr Res. 2011;70:578–583.

31.

Ramos N, Skeete F, Haas JP, Hutzler L, Slover J, Phillips M, Bosco J. Surgical
site infection prevention initiative – patient attitude and compliance. Bull NYU
Hosp Jt Dis. 2011;69:312–315.

32.

Ritz J, Pashnik B, Padula C, Simmons K. Effectiveness of 2 methods of
chlorhexidine bathing. J Nurs Care Qual. 2012;27:171–175.

33.

Roberts RR, Hota B, Ahmad I, Scott RD, 2nd, Foster SD, Abbasi F, Schabowski
S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB,
Weinstein RA. Hospital and societal costs of antimicrobial-resistant infections in
a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect
Dis. 2009;49:1175–1184.

34.

Silva LV, Araujo MT, Santos KR, Nunes AP. Evaluation of the synergistic
potential of vancomycin combined with other antimicrobial agents against
methicillin-resistant Staphylococcus aureus and coagulase-negative
Staphylococcus spp strains. Mem Inst Oswaldo Cruz. 2011;106:44–50.

35.

Steinberg D, Heling I, Daniel I, Ginsburg I. Antibacterial synergistic effect of
chlorhexidine and hydrogen peroxide against Streptococcus sobrinus,
Streptococcus faecalis and Staphylococcus aureus. J Oral Rehabil. 1999;26:151–
156.

36.

Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Walsh TJ, Roilides E.
Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin,
and polymorphonuclear neutrophils against Aspergillus fumigatus. Antimicrob
Agents Chemother. 2011;55:5923–5929.

37.

Stinner DJ, Noel SP, Haggard WO, Watson JT, Wenke JC. Local antibiotic
delivery using tailorable chitosan sponges: the future of infection control? J
Orthop Trauma. 2010;24:592–597.
104

38.

Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS, 2nd. Monotherapy or
combination therapy? The Pseudomonas aeruginosa conundrum.
Pharmacotherapy. 2011;31:598–608.

105

Appendix B
Chitosan Coating to Enhance the Therapeutic Efficacy of Calcium Sulfate-Based
Antibiotic Therapy in the Treatment of Chronic Osteomyelitis

Introduction
Infections of bone and indwelling orthopaedic devices are recalcitrant to
conventional antibiotic therapy irrespective of the acquired resistance status of the
offending bacterial strain (1). There are several reasons for this, but one primary
contributing factor is formation of a bacterial biofilm, the presence of which confers a
therapeutically relevant degree of intrinsic resistance to both host defenses and
conventional antibiotics (2, 3). For this reason, treatment of these infections most often
involves surgical debridement accompanied by some form of localized antibiotic
delivery, the goal of the latter being to achieve a high enough concentration of antibiotic
at the site of infection to overcome this intrinsic resistance while avoiding systemic
toxicity (1, 4).
The manner in which localized antibiotic delivery is accomplished depends on the
extent of debridement required (5). In those cases in which debridement creates a
structurally unstable defect that will ultimately require stabilization using orthopaedic
hardware, the most common delivery vehicle is polymethylmethacrylate (PMMA) bone
cement beads, primarily because PMMA is not biodegradable and therefore does not alter
the wound site prior to reconstruction (6). However, for the same reason, antibiotic-load,
PMMA beads must be removed before reconstruction. Additionally, PMMA has a poor
elution profile characterized by an initial bolus release of relatively high concentrations
followed by a rapid decline to sub-inhibitory concentrations. Antibiotic concentration
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recovered is also poor, thus adding considerable cost without therapeutic benefit. Thus, a
primary goal in efforts to improve PMMA as a delivery vehicle is to increase porosity to
an extent that prolongs the period during which antibiotic levels remain significantly
above the breakpoint minimum inhibitory concentration (MIC) for any given antibiotic.
We demonstrated that this is possible by incorporating xylitol, an inexpensive and
biologically insert disaccharide with limited anti-biofilm properties in and of itself, into
PMMA along with the appropriate antibiotics (7).
Alternatively, in cases in which the debridement required is not so extensive that
it creates a structurally unstable defect, it is preferable to use a biodegradable delivery
matrix, thereby avoiding the need for a second procedure to remove the matrix prior to
reconstruction (6). A common alternative in such cases is calcium sulfate (CaSO 4) αhemihydrate, a biodegradable and biocompatible ceramic that can also be loaded with
water-soluble antibiotics (8, 9, 10). Dissolution of CaSO4 also provides an
osteoconductive environment that enhances vascular ingrowth and osteogenesis. Also,
the antibiotic concentration recovered is higher by comparison to PMMA. However, the
elution profile is still characterized by an initial burst that quickly diminishes as the
CaSO4 dissolves (11, 12). In fact, the decline is generally even more rapid than that
observed with PMMA. Thus, the goal in this case is also to prolong elution, but the
approach to doing so is different in that it is necessary to slow dissolution and thereby
limit rather than enhance antibiotic elution. Slowing dissolution would also limit the
osmotic effect in the localized wound environment that can lead to formation of a seroma
that requires surgical drainage (13).
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To accomplish this task, we explored the use of chitosan as a coating for
antibiotic-loaded CaSO4 beads. Chitosan is a biocompatible polymer that degrades into
simple sugars by enzymatic hydrolysis. It is produced commercially by deacetylation of
chitin (Fig. 1), the structural element of the exoskeleton of crustaceans, and it is available
commercially in a highly purified form for biomedical applications (14). It is also
currently used as an FDA-approved hemostatic agent (HemCon Medical Technologies,
Portland, OR) to control hemorrhaging of battlefield injuries (15, 16). Depending on the
degree of acetylation and molecular weight, chitosan’s elution and degradation
characteristics are highly "tunable", and it can be produced in alternative forms that
include films appropriate for coating orthopaedic implants as a means of preventing
infection (17, 18). Additionally, chitosan itself has antibacterial properties (19, 20) and
promotes wound healing (21). Indeed, a chitosan sponge developed by our group recently
received FDA clearance for marketing as a wound dressing (see 510(K) at the FDA
website http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id
=K112191). Thus, chitosan offers many advantages as a coating for calcium sulfate and
as a stand-alone antibiotic delivery vehicle. Chitosan has not yet been approved by the
FDA for this specific purpose, but we and others have begun to explore these advantages
(17, 22, 23). In this manuscript, we report the results of some of these studies carried out
in the specific context of using chitosan-coated CaSO4 pellets containing daptomycin in
the post-debridement treatment of chronic osteomyelitis.
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Deacetylated Unit

Acetylated Unit

2-amino2-deoxy-β-D-glycopyranose

β-(1-4) linked 2-acetamido2-deoxy-β-D-glucopyranose

Coated

Uncoated

Figure 1. Chitosan coating of calcium sulfate pellets. Top: Structural characteristics of acetylated vs.
deacetylated chitosan. Bottom: Comparison of coated vs. uncoated calcium sulfate pellets.

Materials and Methods
CaSO4 formulation and characterization. The CaSO4 α-hemihydrate (Osteoset®,
Wright Medical Technology, Arlington, TN) pellet formulations evaluated in these
experiments included CaSO4 alone, CaSO4 coated with chitosan (Cognis, Chitopharm®;
Monheim, Germany; degree of deacetylation: 78%, average molecular weight: 2.1×102
kDa), CaSO4 loaded with daptomycin (Cubicin®; Cubist Pharmaceuticals, Lexington,
MA) and CaSO4 with both daptomycin and a chitosan coating. We chose to focus on
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daptomycin because we have previous experience with this antibiotic in our studies
focusing on PMMA and because it exhibits greater therapeutic efficacy than many other
antibiotics in the context of a biofilm (3).
Pellets without antibiotic were created by mixing 12 gm CaSO 4 in 3.71 ml of
0.172M K2SO4. The resulting putty was cast into a custom made, 4 mm by 10 mm,
cylindrical, silicone template (Sylgard 170 Silicone Elastomer, Dow Corning; Midland,
MI), which approximates the size of an excised rabbit radial segment (see below), and
allowed to cure for 15 min. For antibiotic loading, 8.5 gm of CaSO4 putty was added to
3.09 ml of K2SO4 and mixed for one minute before adding 1.5 gms of daptomycin
powder (Cubicin®, Cubist Pharmaceuticals, Lexington, MA) and placing the slurry into
the mold. Thus, the weight to volume ratio in both cases was ~3.2, with daptomycin
representing 15% of the total weight in daptomycin-loaded pellets. The daptomycin
loaded CaSO4 was allowed to cure for 45 min, the increased time being necessary due to
the presence of antibiotic. For chitosan coatings, CaSO 4 pellets were submerged in a
viscous solution of 4 w/v% chitosan in 0.26 M lactic acid. The pellet was then allowed to
completely dry in a desiccator at room temperature. The coating procedure was repeated
five times to provide uniform coverage of the chitosan, with the average coating
thickness ranging from 0.4 to 0.8 mm. All pellets were stored at room temperature in a
desiccator until elution testing or evaluation in our rabbit osteomyelitis model.
To determine the effect of chitosan coating on the elution of daptomycin, in vitro
elution comparisons were performed by dividing daptomycin loaded pellets into sample
sets consisting of four pellets each, with each set of four being repeated in triplicate. Each
set was placed in a flask containing 6 ml of sterile phosphate buffered saline (PBS) and
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incubated at 37°C with constant shaking for 10 days. At 24 hour intervals, the entire
volume of PBS was removed and replaced with 6 ml of fresh, sterile PBS, thus ensuring
that antibiotic obtained on any given sampling day was eluted since the previous
sampling day. Samples were stored at -20°C until analysis using high pressure liquid
chromatography (HPLC) with a C8 column and an acidic acetonitrile-salt mobile phase
(7, 24).
Rabbit osteomyelitis model. All in vivo experiments were done in accordance with the
policies of the Public Health Service (PHS) on the care and use of laboratory animals, the
Animal Welfare Act, and the NIH Guide for the Care and Use of Laboratory Animals.
All animal procedures were reviewed and approved by the Institutional Animal Care and
Use Committee of the University of Arkansas for Medical Sciences and carried out in an
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
accredited facility.
Therapeutic efficacy was assessed using an established rabbit model of
postsurgical osteomyelitis (7, 25). Briefly, a 1-cm midradial segment was surgically
excised from each of 24 male, New Zealand White rabbits. The infection was initiated in
all rabbits by injection of 106 colony-forming units (cfu) of the Staphylococcus aureus
osteomyelitis isolate UAMS-1 directly into the intramedullary canal in a total volume of
10 µl of sterile PBS. The segment was then returned to the radial defect in its original
orientation and the wound closed. After 3 weeks, radiographs were obtained from all
rabbits prior to opening the incision site and performing a minimal debridement limited
to removal of the 1-cm infected bone segment and irrigation with 50 ml of sterile PBS.
This debridement was minimized to ensure that the infection was not cleared by
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debridement alone. Samples for bacteriological analysis were taken from the bone and
surrounding soft tissue before and after debridement. After debridement, the defect was
filled with a single pellet manufactured to fit snugly into the 1-cm defect (Figure 1).
Rabbits were randomized by treatment group, with only one technician in the operating
suite aware of the CaSO4 formulation placed into each rabbit following debridement.
Assessment of relative therapeutic efficacy. Pellets were left in place for 3 weeks
without any additional form of antibiotic treatment, at which time rabbits were humanely
euthanized and the surgical limb harvested for X-ray, histological, and bacteriological
analysis as previously described (7). For bacteriological analysis, samples were collected
by swab from the infection site and used to inoculate tryptic soy agar (TSA) without
antibiotic selection. To achieve a quantitative comparison, swabs were used to
comprehensively inoculate the first quadrant of a TSA plate, which was then struck for
isolated colonies using standard bacteriological techniques. The relative amount of
growth was scored after 24 h at 37°C based on growth in the first quadrant only (1+) to
growth across all four quadrants (4+). The scores obtained with all swabs from each
experimental animal were then averaged to obtain a single bacteriological score. The
same scoring protocol was employed immediately before and after debridement, thus
yielding three bacteriological scores for each rabbit. However, because the critical issue
was the relative therapeutic response, the primary analysis was based on scores for each
rabbit obtained after debridement and after treatment. As a control for variation between
rabbits, these scores were used to calculate the average change in bacteriological score
between these time points.
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X-rays were scored by an orthopedic surgeon blinded to the infection status of
each rabbit. Scores were based on evidence of periosteal elevation, sequestration,
architectural deformation, and deformation of soft tissue as previously described (7).
Each parameter was scored on a 5-point scale (0 to 4), with 4 representing the most
severe evidence of disease. Scores were then averaged to obtain a single radiographic
score for each rabbit at both the debridement and post-treatment time points. As with our
bacteriological analysis, we then calculated the average change in overall radiographic
scores within each experimental group.
After collection of the final samples for bacteriological analysis, the surgical limb
was removed and processed for histological analysis by hematoxylin and eosin (H&E)
staining and by Gram stain (25). However, the histopathological scoring system was
modified as previously described to address the inclusion of a treatment phase in these
experiments (7). A separate score was also derived for each rabbit based on Gram stain
and the relative abundance of intraosseous Gram-positive cocci. Given the
osteoconductive properties of CaSO4, we also assessed new bone growth as a separate
experimental parameter, but only in the post-treatment group because this was the only
time point at which all animals had been exposed to CaSO4 (7).
Statistical analysis. We determined the effect of chitosan coating on daptomycin elution
between the different groups using two way ANOVA with Tukey’s post hoc analysis.
Similarly, two way ANOVA was used to determine whether various CaSO4 formulations
differed with respect to bacteriology, X ray, histology, and Gram stain scores. If
significant, Tukey’s post hoc tests were used to perform pairwise testing. Statistical
significance for all analyses was determined using an α level of 5%.
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Results
Our in vitro elution studies demonstrate two important changes in the CaSO4
elution profile of daptomycin that were attributable to coating with chitosan. First, the
initial bolus release was reduced approximately 10-fold (Figure 2). However, the
maximum concentration observed after one day of elution even with chitosan coating was
~1,000 µg per ml or ~1,000 times (1,000X) the breakpoint MIC for daptomycin.
Secondly, without chitosan coating, the concentration of antibiotic eluted from the pellets
fell rapidly, going below an arbitrarily chosen standard of 100 times (100X) the
breakpoint MIC for daptomycin by day 3. In contrast, with chitosan-coated CaSO4
pellets, the concentration of daptomycin remained well above this standard even after 10
days (Figure 2). In fact, during the period between 6 and 10 days, the amount of
daptomycin obtained with chitosan-coated pellets was >50-fold higher than that obtained
with uncoated pellets.

Figure 2. Elution profile as a function of chitosan coating. Daptomycin concentrations were determined
using HPLC at daily intervals after complete replacement of the elution buffer. The breakpoint MIC for a
daptomycin-sensitive strain of S. aureus is 1.0 µg per ml.
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Taken together, these results confirm that coating with chitosan is an effective method to
extend antibiotic elution from CaSO4 without an unacceptable compromise of the
maximum levels obtainable during the early stages of elution.
Bacteriological analysis confirmed that the infection status in all experimental groups
was roughly equivalent both before (data not shown) and immediately after debridement
(Figure 3). It also demonstrated that overall bacteriological scores were significantly
lower in the group treated with chitosan-coated pellets containing daptomycin than in the
untreated (CaSO4 alone) control group. There was no statistically significant difference
between the untreated control group and the group treated with uncoated, daptomycinloaded pellets, which further suggests that coating with chitosan did have a positive
therapeutic effect. However, when the results were evaluated based on the change in
bacteriological scores between the time of debridement and after treatment, there was no
significant difference between the daptomycin-treated groups depending on whether
CaSO4 pellets were coated with chitosan (Figure 3).
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Figure 3. Analysis based on average bacteriological scores. Results are shown for each experimental group
immediately following debridement, after treatment, and as the change between these two time points. 0U,
0C, 15U, and 15C refer to CaSO4 pellets lacking any or including 15% daptomycin (0 vs. 15) and with and
without chitosan coating (U vs. C). Boxes indicate the 25th and 75th percentiles for each group and define
the interquartile range (IQR), with the horizontal line indicating the median. Vertical lines define the lowest
and highest data points within 1.5 IQR of the lower and higher quartile respectively, with individual dots
representing single data points outside this range. Numbers within the graph are p values determined as
described in the text.

These same overall trends were also observed when the analysis was based on
overall radiographic scores, although in this case none of the differences between
experimental groups were statistically significant (Figure 4). No such trends were noted
based on overall histopathological scores or Gram stain analysis (Figure 5 and Figure 6).
In fact, the opposite appeared to be true, with overall histopathological scores being
highest in the experimental group treated with chitosan-coated CaSO4. New bone growth
was also comparable in all groups (Figure 7).

116

Figure. 4. Analysis based on average X-ray scores. Results are shown for each experimental group
immediately following debridement, after treatment, and as the change between these two time points. 0U,
0C, 15U, and 15C refer to CaSO4 pellets lacking any or including 15% daptomycin (0 vs. 15) and with and
without chitosan coating (U vs. C). None of the differences observed by X-ray were statistically significant.
Boxes indicate the 25th and 75th percentiles for each group and define the interquartile range (IQR), with
the horizontal line indicating the median. Vertical lines define the lowest and highest data points within 1.5
IQR of the lower and higher quartile respectively, with individual dots representing single data points
outside this range. Numbers within the graph are p values determined as described in the text.

Figure. 5. Analysis based on average histopathological scores. Results are shown for each experimental
group immediately following debridement, after treatment, and as the change between these two time
points. Numbers within the graph are p values determined as described in the text. 0U, 0C, 15U, and 15C
refer to CaSO4 pellets with and without daptomycin (0 vs. 15) and with and without chitosan coating (U vs.
C). Boxes indicate the 25th and 75th percentiles for each group and define the interquartile range (IQR),
with the horizontal line indicating the median. Vertical lines define the lowest and highest data points
within 1.5 IQR of the lower and higher quartile respectively, with individual dots representing single data
points outside this range. Numbers within the graph are p values determined as described in the text.
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Figure. 6. Analysis based on average Gram stain scores. Results are shown for each experimental group
immediately following debridement, after treatment, and as the change between these two time points.
None of the differences observed by Gram stain were statistically significant. 0U, 0C, 15U, and 15C refer
to CaSO4 pellets with and without daptomycin (0 vs. 15) and with and without chitosan coating (U vs. C).
Boxes indicate the 25th and 75th percentiles for each group and define the interquartile range (IQR), with
the horizontal line indicating the median. Vertical lines define the lowest and highest data points within 1.5
IQR of the lower and higher quartile respectively, with individual dots representing single data points
outside this range. Numbers within the graph are p values determined as described in the text.

Figure 7. Assessment of new bone growth. Results are shown for individual rabbits within each
experimental group following treatment based on histopathological analysis. 0U, 0C, 15U, and 15C refer to
CaSO4 pellets lacking any or including 15% daptomycin (0 vs. 15) and with and without chitosan coating
(U vs. C). None of the differences between groups were statistically significant.
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Discussion
The in vitro elution profile we targeted in our earlier studies focusing on PMMA
(a maximum concentration at least 100 times (100X) the breakpoint MIC and a sustained
concentration defined after 10 days of continuous elution of at least 5X the breakpoint
MIC) was chosen arbitrarily based on the recognized need to significantly exceed MIC of
the offending bacterial strain in the specific context of a biofilm. However, when we
transitioned to in vivo studies, it was also found to be inadequate based on a lack of any
significant therapeutic response (7). For that reason, we increased the amount of
daptomycin to 4 gm per 40 gm packet of PMMA. This resulted in an elution profile with
a maximum concentration just over 1000 µg per ml and a sustained concentration just
under 100 µg per ml, and with this formulation we did observe an enhanced therapeutic
effect (7). Based on this, we attempted to achieve a similar elution profile in the
experiments reported here, a goal that we were able to accomplish only by coating CaSO4
pellets with chitosan.
The more critical issue is whether this enhanced elution profile can be correlated
with an improved therapeutic outcome, and we believe the results we report support the
conclusion that this is also true. This is based primarily on bacteriological analysis, which
confirmed a statistically significant difference in the reduction in bacterial load in rabbits
treated with chitosan-coated CaSO4 pellets containing daptomycin vs. rabbits treated with
calcium sulfate alone. Importantly, this was not true of any other experimental group
including rabbits treated with uncoated pellets containing daptomycin. We consider this a
particularly significant observation given our purposeful use of a minimal debridement
protocol.
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The results were much less clear when the analysis was based on radiographic or
histopathological evidence of disease or, for that matter, the presence of intraosseous
Gram-positive cocci. This was also true in our experiments focusing on the use of xylitol
as a means of enhancing antibiotic elution from PMMA (7), and as noted in that report
this is perhaps not surprising given that we used a high bacterial inoculum to purposefully
establish a severe infection in all rabbits and limited our debridement to a degree meant
to ensure that this infection status was maintained at the outset of the treatment period.
Practicality also imposes a time frame on studies like those we report, and it remains
unclear whether a longer course of therapy, or whether combining our protocol with
systemic therapy, would have further enhanced the therapeutic outcome as assessed based
on these parameters. Similarly, there was little difference in overall Gram stain scores,
but as was also noted in our previous report (7), these scores were based on the relative
abundance of intraosseous Gram-positive cocci, and this does not mean that the bacteria
present were viable. In fact, this seems unlikely given the definitive changes observed
based on bacteriological scores, which were in fact based on the relative abundance of
viable bacteria recovered from each rabbit.
Finally, new bone growth was also comparable between all experimental groups,
but the significance of this, if any, must be interpreted with caution for several reasons.
First, we did not include an experimental group without CaSO4, so the extent to which
calcium sulfate alone promotes new bone growth remains unclear. However, perhaps the
more important point is that, if any of the new bone growth observed is attributable to
CaSO4, it was not compromised by the presence of a chitosan coating, thus suggesting
that the improved bacteriological outcome would not compromise other potential benefits
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of CaSO4 in the context of localized antibiotic therapy in the treatment of chronic
osteomyelitis. In fact, while none of the differences in Gram-stain scores reached
statistical significance, the scores were lowest in the two groups treated with chitosancoated pellets irrespective of the presence of daptomycin, a result that suggests chitosan
itself may offer independent therapeutic benefits.
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Appendix C
Animal Use Protocol Approvals

1. The University of Memphis Institutional Animal Care and Use Committee Protocol
Action Form
Protocol 0720 Approval: Antibiotic-loaded biopolymer sponge for prevention of
polymicrobial wound infection (Rat Model)
2. The University of Memphis Institutional Animal Care and Use Committee Protocol
Action Form
Protocol 0738 Approval: Biopolymer paste biocompatibility (Rat Model)
3. The University of Arkansas for Medical Science Institutional Animal Care and Use
Committee Protocol Approval Letter
Protocol 3641 Approval: Antibiotic-loaded chitosan devices for wound infection
prevention (Mouse Model)
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IACUC PROTOCOL ACTION FORM
To:

Warren Haggard

From

Institutional Animal Care and Use Committee

Subject

Animal Research Protocol

Date

3-18-13

The Institutional Animal Care and Use Committee (IACUC) has taken the following action
concerning your Animal Research Protocol No.

0720 (Antibiotic loaded sponge ...)
Your proposal is approved for the following period:0727
From:

March 18, 2013

To:

March 17, 2016

Your protocol is not approved for the following reasons (see attached memo).

Your protocol is renewed without changes for the following period:
From:

To:

Your protocol is renewed with the changes described in your IACUC Animal Research Protocol
Revision Memorandum dated
for the following period:
From:

To:

Your protocol is not renewed and the animals have been properly disposed of as described in your
IACUC Animal Research Protocol Revision Memorandum dated
.

___________________________________________
Prof. Guy Mittleman, Chair of the IACUC

Dr. Karyl Buddington, University Veterinarian
And Director of the Animal Care Facilities

IACUC PROTOCOL ACTION FORM
To:

Warren O. Haggard

From

Institutional Animal Care and Use Committee

Subject

Animal Research Protocol

Date

10-30-13

The institutional Animal Care and Use Committee (IACUC) has taken the following action
concerning your Animal Research Protocol No.
Biopolymer paste biocompatibility (0738)

Your proposal is approved for the following period:0727
From:

October 30, 2013

To:

October 29, 2016

Your protocol is not approved for the following reasons (see attached memo).

Your protocol is renewed without changes for the following period:
From:

To:

Your protocol is renewed with the changes described in your IACUC Animal Research Protocol
Revision Memorandum dated
for the following period:
From:

To:

Your protocol is not renewed and the animals have been properly disposed of as described in your
IACUC Animal Research Protocol Revision Memorandum dated
.

___________________________________________
Prof. Guy Mittleman, Chair of the IACUC

Dr. Karyl Buddington, University Veterinarian
And Director of the Animal Care Facilities

